

# Panorama of the distal myopathies

Marco Savarese<sup>1,2</sup>, Jaakko Sarparanta<sup>1,2</sup>, Anna Vihola<sup>1,2,3</sup>,  
Per Harald Jonson<sup>1,2</sup>, Mridul Johari<sup>1,2</sup>, Salla Rusanen<sup>1,2</sup>, Peter Hackman<sup>1,2</sup>,  
Bjarne Udd<sup>1,2,4</sup>

<sup>1</sup> Folkhälsan Research Center, Helsinki, Finland; <sup>2</sup> Department of Medical Genetics, Medicum, University of Helsinki, Helsinki, Finland; <sup>3</sup> Neuromuscular Research Center, Department of Genetics, Fimlab Laboratories, Tampere, Finland; <sup>4</sup> Department of Neurology, Vaasa Central Hospital, Vaasa, Finland

Distal myopathies are genetic primary muscle disorders with a prominent weakness at onset in hands and/or feet. The age of onset (from early childhood to adulthood), the distribution of muscle weakness (upper versus lower limbs) and the histological findings (ranging from nonspecific myopathic changes to myofibrillar disarrays and rimmed vacuoles) are extremely variable. However, despite being characterized by a wide clinical and genetic heterogeneity, the distal myopathies are a category of muscular dystrophies: genetic diseases with progressive loss of muscle fibers. Myopathic congenital arthrogyriosis is also a form of distal myopathy usually caused by focal amyoplasia.

Massive parallel sequencing has further expanded the long list of genes associated with a distal myopathy, and contributed identifying as distal myopathy-causative rare variants in genes more often related with other skeletal or cardiac muscle diseases.

Currently, almost 20 genes (*ACTN2*, *CAV3*, *CRYAB*, *DNAJB6*, *DNM2*, *FLNC*, *HNRNP1A1*, *HSPB8*, *KHLH9*, *LDB3*, *MATR3*, *MB*, *MYOT*, *PLIN4*, *TIA1*, *VCP*, *NOTCH2NLC*, *LRP12*, *GIPSI*) have been associated with an autosomal dominant form of distal myopathy. Pathogenic changes in four genes (*ADSSL*, *ANO5*, *DYSF*, *GNE*) cause an autosomal recessive form; and disease-causing variants in five genes (*DES*, *MYH7*, *NEB*, *RYR1* and *TTN*) result either in a dominant or in a recessive distal myopathy. Finally, a digenic mechanism, underlying a Welander-like form of distal myopathy, has been recently elucidated. Rare pathogenic mutations in *SQSTM1*, previously identified with a bone disease (Paget disease), unexpectedly cause a distal myopathy when combined with a common polymorphism in *TIA1*.

The present review aims at describing the genetic basis of distal myopathy and at summarizing the clinical features of the different forms described so far.

**Key words:** distal myopathy, rimmed vacuoles, myofibrillar myopathy

Received: November 11, 2020  
Accepted: November 11, 2020

## Correspondence

Bjarne Udd  
Folkhälsan Research Center, Biomedicum 1, Haartmaninkatu  
8, 00290 Helsinki, Finland. Tel.: +358 2941 25629.  
E-mail: bjarne.udd@netikka.fi

## Conflict of interest

The Authors declare no conflict of interest

**How to cite this article:** Savarese M, Sarparanta J, Vihola A, et al. Panorama of the distal myopathies. *Acta Myol* 2020;39:245-65. <https://doi.org/10.36185/2532-1900-028>

© Gaetano Conte Academy - Mediterranean Society of Myology



OPEN ACCESS

This is an open access article distributed in accordance with the CC-BY-NC-ND (Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International) license. The article can be used by giving appropriate credit and mentioning the license, but only for non-commercial purposes and only in the original version. For further information: <https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en>

## Introduction

The term distal myopathy refers to a long list of genetic muscle diseases presenting at the onset with weakness of distal extremities, usually combined with progressive atrophy of the corresponding distal muscles. Other muscles, including proximal muscles and/or cardiac and respiratory muscles, can be affected at a later stage of the disease. The clinical phenotype is extremely variable, ranging from severe forms with earlier onset and loss of ambulation to very mild late adult onset forms. Other muscle

diseases (genetically determined or acquired) may present with a distal phenotype, making the diagnostic process more complex.

Although two patients with weakness in hands and in legs or feet were first described as distal myopathy by Gowers over 100 years ago<sup>1</sup>, only in 1998 the first genetic defect underlying a distal myopathy was identified<sup>2</sup>. Ten years ago, in 2010, only fourteen causative genes were known. In the last years, massive parallel sequencing has contributed to identify disease-causing variants in novel genes and to elucidate the first example of a digenic mechanism causing a distal myopathy (Tab. I). At the same time, the number of causative variants, identified in large resequencing projects, has exponentially increased<sup>3-7</sup>. Interestingly, most currently known genes are also responsible for separate different clinical entities, confirming the extreme phenotypic divergence observed in the field of genetic myopathies<sup>8</sup>.

More advanced histopathological techniques and refined cell and molecular biology studies have resulted in a better understanding of the pathophysiology of distal myopathies. Clinical, histopathological, and imaging features of each form have been partly clarified, addressing the diagnosis, and supporting a proper interpretation in case of novel variants identified in previously known genes.

## Adult – late onset distal myopathies

### *Welander distal myopathy (WDM) – TIAI*

WDM was first described in several Swedish families in 1951 as an autosomal dominant late adult-onset (usually over 50 years) disease with a prominent early involvement of fingers and wrist extensors<sup>9</sup>. As the disease progresses, weakness involves also finger flexors, toe and ankle extensors. The disease course is usually slowly progressive, and patients remain ambulant. Histopathology features include rimmed vacuoles.

A missense variant (p.E384K) in *TIAI* gene causing the disease was identified in 2013<sup>10</sup>. *TIAI* encodes an RNA-binding protein involved in the alternative splicing of specific pre-mRNAs<sup>11-14</sup>, and is a key molecule in stress granules, regulators of RNA-translation metabolism that show altered dynamics in WDM<sup>10</sup>.

### *Digenic SQSTM1 and TIAI mediated distal myopathy*

Patients with a Welander distal myopathy phenotype but negative for causative rare mutations in *TIAI* were discovered to have instead a common polymorphism in the *TIAI*, which, with a population frequency of 1%, could not be the cause of the disease. Further gene pan-

el sequencing in these patients showed the presence of *SQSTM1* mutations previously known to cause the Paget's disease of the bone, a dominant disease with reduced penetrance<sup>15</sup>. Functional studies showed that the *SQSTM1* gene product, p62, interferes with the same stress granule dynamics pathway as *TIAI* explaining the background for the digenic mechanism<sup>15</sup>. This genetic combination of rare *SQSTM1* causative variants and the common *TIAI* polymorphism did not result in a Paget disease of the bone but caused the canonical Welander phenotype. On the other hand, a cohort of 50 patients with Paget disease of the bone carrying the same *SQSTM1* mutations did not have the *TIAI* polymorphism<sup>15</sup>.

### *Tibial muscular dystrophy (Udd myopathy) – the first human titinopathy*

Tibial muscular dystrophy (TMD) or Udd myopathy was described in 1993 in Finnish patients<sup>16</sup>. Weakness in ankle dorsiflexion and atrophy of anterior lower leg muscles (often asymmetric) start after age of 35 or much later. Progression is slow and walking is usually preserved. Extensor digitorum brevis and hand muscles are normally spared. Serum CK is normal or mildly elevated and muscle imaging shows fatty degeneration in anterior tibial muscles and at later stage in all long toe extensors, hamstring and medial gastrocnemius muscles.

Muscle biopsy shows myopathic changes with acid phosphatase, ubiquitin, p62 and LC3 positive in the affected muscles, but in preserved muscles there is only a slight increase of internal nuclei.

In Finnish TMD patients, a common founder mutation (FINmaj) in the last exon of titin gene (*TTN*) was identified in 2002<sup>17</sup>. FINmaj is a complex 11-bp insertion–deletion resulting in substitution of four amino acids without any frameshift and preserving the downstream amino acid sequence. Following the FINmaj identification, missense variants in the same exon (364) were also identified in non-Finnish patients<sup>17-19</sup>.

*TTN* gene encodes titin, the third filament system of the sarcomere<sup>20</sup>. Titin interacts with several important proteins, including calpain-3 that binds the C-terminal portion of titin<sup>21,22</sup>. Through a large number of alternative splicing events, *TTN* encodes for a large number of different transcripts, developmental-stage or tissue specific<sup>23,24</sup>. Reflecting the size and complexity of titin, causative variants result in allelic diseases affecting skeletal muscle, heart or both of them, referred to as 'titinopathies'<sup>25,26</sup>. Dominant titinopathies include the aforementioned TMD, and the hereditary myopathy with early respiratory failure (HMERF) caused by missense variants in exon 344<sup>17,27-29</sup>. Recessive titinopathies include a wide spectrum of diseases with a prenatal, congenital, childhood or later onset<sup>30,31</sup>. A recessive form of early/juvenile onset recessive distal titinopathy is further

**Table I.** List of distal myopathies and causative genes.

Clinical entity	Gene(s)	Transmission	References
<b>Adult – late onset distal myopathies</b>			
Welander distal myopathy	<i>TIA1</i>	AD	Hackman et al., 2012
Digenic SQSTM1 and TIA1 mediated distal myopathy	<i>SQSTM1+TIA1</i>	DG	Lee et al., 2018
Tibial muscular dystrophy (Udd myopathy)	<i>TTN</i>	AD	Hackman et al., 2002
Vocal cord and pharyngeal distal myopathy	<i>MATR3</i>	AD	Senderek et al., 2009
Distal Actininopathy	<i>ACTN2</i>	AD	Savarese et al., 2019
Distal Myopathy with sarcoplasmic bodies	<i>MB</i>	AD	Olive et al., 2019
Oculopharyngeal distal myopathy	<i>NOTCH2NLC, LRP12 and GIPC1</i>	AD	Deng et al., 2020; Ishiura et al., 2019; Saito et al., 2020; Sone et al., 2019
PLIN4 mutated distal myopathy	<i>PLIN4</i>	AD	Ruggieri et al. 2020
VCP distal myopathy	<i>VCP</i>	AD	Palmio et al 2011
<b>Myofibrillar distal myopathies</b>			
Distal myopathy with myotilin defect	<i>MYOT</i>	AD	Penisson-Besnier et al., 2006
Late onset distal myopathy (Markesbery-Griggs, Zaspopathy)	<i>LDB3</i>	AD	Griggs et al., 2007
Desminopathy	<i>DES</i>	AD > AR	Sjoberg et al., 1999
Alpha-B crystallin-mutated distal myopathy	<i>CRYAB</i>	AD	Reichlich et al. 2010
<b>Early adult onset distal myopathies</b>			
Miyoshi myopathy	<i>DYSF</i>	AR	Liu et al., 1998
Recessive distal titinopathy	<i>TTN</i>	AR	Evila et al., 2017
Distal myopathy with rimmed vacuoles (Nonaka and GNE myopathy)	<i>GNE</i>	AR	Kayashima et al., 2002
Distal ABD-filaminopathy	<i>FLNC</i>	AD	Duff et al., 2011
DNAJB6 distal myopathy	<i>DNAJB6</i>	AD	Ruggieri et al., 2015 - Palmio et al., 2020
Rimmed vacuolar neuromyopathy	<i>HSPB8</i>	AD	Ghaoui et al., 2016
ANO5 distal muscular dystrophy	<i>ANO5</i>	AR	Bolduc et al., 2010
RYR1 mutated calf predominant distal myopathy	<i>RYR1</i>	AD/AR	Laughlin et al., 2017 - Jokela et al., 2019
<b>Early-childhood onset distal myopathies</b>			
Early onset distal myopathy (Laing)	<i>MYH7</i>	AD > AR	Meredith et al., 2004
Early onset distal myopathies with nebulin defect	<i>NEB</i>	AR > AD	Wallgren-Pettersson et al., 2007, Kiiski et al., 2019
Early onset ADSSL distal myopathy	<i>ADSSL</i>	AR	Park et al., 2016
Early onset distal myopathy with KLHL9 mutations	<i>KLHL9</i>	AD	Cirak et al., 2010
<b>Other myopathies and dystrophies with distal weakness</b>			
Distal myopathy with caveolin defect	<i>CAV3</i>	AD	Tateyama et al., 2002
DNM2 related distal myopathy	<i>DNM2</i>	AD	Bitoun et al., 2005

AD: autosomal dominant; AR: autosome recessive; DG: digenic

discussed below in this review. With the increasing number of reported patients, first insights on the genotype-phenotype correlation are achieved<sup>30</sup>. *TTN* variants are also associated with dilated and hypertrophic cardiomyopathy<sup>32,33</sup>.

#### Vocal cord and pharyngeal distal myopathy – *MATR3*

First described in a large North American family<sup>34</sup>

and later in a large Bulgarian pedigree<sup>35</sup>, vocal cord and pharyngeal distal myopathy (VCPDM) is characterized by adult-onset (between 35 and 60 years) distal weakness and weakness of vocal cord and pharyngeal muscles. Limb weakness can be asymmetric and the phenotype is highly variable in terms of age of onset, progression and muscle weakness distribution<sup>34,36,37</sup>. Most patients develop respiratory failure<sup>38</sup>. CK levels are normal or mildly

elevated. EMG shows myopathic changes and rimmed vacuoles are present in the biopsy. Muscle MRI shows a predominant involvement of the lower legs both anterior and posterior compartment and hamstrings in thighs<sup>39</sup>.

The underlying re-occurring p.S85C mutation was identified in *MATR3* gene<sup>35</sup>. *MATR3* encodes matrin-3, a protein located in the nuclear matrix where it regulates several processes related to gene expression, RNA splicing and export of RNA and nuclear proteins<sup>40,41</sup>. Variants in *MATR3* have also been identified in patients with amyotrophic lateral sclerosis (ALS)<sup>42</sup>.

#### *Distal Actininopathy – ACTN2*

Distal actininopathy is an autosomal dominant, adult onset distal myopathy starting usually with foot drop. The disease later progresses to proximal lower limb muscles while upper limbs remain relatively spared<sup>43</sup>. Serum CK levels are mildly elevated and muscle biopsy shows rimmed vacuoles with some myofibrillar disarrays and undulation of the Z-disk on electron microscopy<sup>43</sup>.

The underlying genetic defects in the four families reported so far are heterozygous missense variants in the *ACTN2* gene. *ACTN2* encodes alpha-actinin2, a structural molecule of the Z-disks that interacts with titin and acts a scaffold of many other Z-disk located proteins such as myotilin<sup>44-47</sup>.

Variants in *ACTN2* also cause congenital myopathy with structured cores and Z-line abnormalities<sup>48</sup>. Moreover, dilated cardiomyopathy and hypertrophic cardiomyopathy have been associated with missense variants in *ACTN2*<sup>49-53</sup>.

#### *Distal Myopathy with sarcoplasmic bodies – MB*

In 1980 Edström et al. published a Swedish family with this title<sup>54</sup>. Only recently, the genetic cause of the disease was identified with one unique causative variant in Myoglobin (*MB*), reoccurring in several unrelated families<sup>55</sup>. In these later studied families, the characteristic muscle pathology was evident but the clinical phenotype was more proximo-distal and not particularly distal<sup>55</sup>.

#### *Oculopharyngeal distal myopathy OPDM – CGG and GGC expansions*

The peculiar combination of severe adult onset distal atrophies in limb muscles and facial weakness, ptosis and dysphagia can occur both in dominant and recessive families and in sporadic patients<sup>56,57</sup>. In the studied patients, the muscle pathology is a rimmed vacuolar myopathy. In the two last years the cause of many Asian dominant families have been clarified as caused by triplet repeat expansions, both CGG and GGC, in three different genes *NOTCH2NLC*, *LRP12* and *GIPCI*<sup>58-61</sup>. The repeats are

translated into aggregating protein products and the host gene functions are not supposed to contribute to the disease mechanism.

#### *PLIN4 mutated distal myopathy – PLIN4*

A large Italian family with an autosomal dominant adult-onset distal myopathy and histopathological features of rimmed vacuoles was first described in 2004<sup>62</sup>. Linkage analysis suggested that the causative gene could have been localized in the 19p13.3 locus<sup>62</sup>.

Recently, Ruggieri et al. identified the underlying genetic defect in the *PLIN4* gene, encoding for perilipin-4<sup>63</sup>. Thirty-one repeats of 99 nucleotides in exon 4 of *PLIN4* encode the 31x33 amino acid amphipathic domain of perilipin-4. An expansion of the normal repeat to 40 × 99 bases, resulting in 297 (9 × 33) extra amino acids, has been identified in the affected members of the family.

Perilipin-4 is a member of the perilipin family, a group of proteins that coat the surface of lipid droplets<sup>64</sup>. Perilipin-4 is highly expressed in skeletal muscle with a possible role in lipid metabolism. The identified repeat expansion in patients with *PLIN4*-related distal myopathy seems to cause a misfolding and leads to protein accumulation in vacuoles disrupting the myofibrillar organization<sup>63</sup>.

#### *VCP distal myopathy – VCP*

Initially described by Palmio and colleagues in a large dominant Finnish family, *VCP*-related distal myopathy has an onset in mid-adulthood mainly affecting anterior leg muscles<sup>65</sup>. After 25 years of disease, the patients became affected by a progressive frontotemporal dementia. None of the patients had signs of Paget disease of the bone. Serum CK levels are normal or slightly elevated. Myopathic changes with rimmed vacuoles are observed in the muscle biopsy. MRI shows degenerative changes of anterior lower leg muscles.

Although a clinical variability has been observed<sup>66-73</sup>, the most common phenotype of pathogenic *VCP* variants is proximal myopathy with scapular winging, Paget disease and frontotemporal dementia (IBMPFD)<sup>74-76</sup>.

## **Myofibrillar distal myopathies**

#### *Distal myopathy with myotilin defect – MYOT*

A late-onset distal myopathy has been associated with heterozygous variants in *MYOT* gene<sup>77-79</sup>. The first symptoms, weakness of ankle dorsiflexion and/or calf muscles, occur after age 50 years but, despite late onset, the further progression can be rapid. Respiratory and cardiac muscles are spared.



Histopathological features are consistent with myofibrillar myopathy and include rimmed and non-rimmed vacuoles, and myofibrillar disorganization with myotilin accumulations<sup>79-81</sup>. Muscle imaging shows that soleus is typically the first muscle affected followed by tibialis anterior and gastrocnemius medialis muscles<sup>82,83</sup>.

The most common causative variants in *MYOT* are missense changes affecting serine and threonine amino acids in the serine rich domain. *MYOT* gene encodes myotilin, a key component of the Z-disc, directly binding F-actin<sup>84</sup>. Some patients have been described as affected by a dominant limb-girdle muscular dystrophy (previously LGMD1A)<sup>85,86</sup>, but distal myopathy is the main phenotype. A proximal muscle involvement is only observed in later stages or in homozygosity for known dominant variants<sup>87,88</sup>. The term ‘spheroid body myopathy’ was also used since the protein aggregates in some cases have the corresponding shape<sup>89,90</sup>.

#### *Late onset distal myopathy (Markesbery-Griggs, Zaspopathy) – LDB3*

The dominant *LDB3*-related distal myopathy usually starts with ankle weakness after the age of 40 years with later involvement of proximal muscles<sup>91-94</sup>. Cardiomyopathy can occur very late; facial and respiratory muscles are preserved. Muscle biopsy reveals myofibrillar myopathy with rimmed and non-rimmed vacuoles<sup>95</sup>. Myofibrillar protein accumulations are similar with myotilinopathy and desminopathy<sup>96</sup>.

*LDB3* encodes the lim domain-binding 3 protein, also called Z-band alternatively spliced PDZ motif-containing protein (ZASP) that interacts with other Z-disk proteins<sup>97,98</sup>. Hypertrophic and dilated cardiomyopathies (with or without left ventricular noncompaction) are allelic disorders<sup>99,100</sup>.

#### *Desminopathy – DES*

Desmin-related distal myopathy is a myofibrillar myopathy with cytoplasmic accumulation of desmin in cardiac and skeletal muscles. The first family was described in 1943 long before the gene was known<sup>101,102</sup>. Cardiomyopathy and cardiac conduction defects are frequent, and the weakness/atrophy involves both hands and lower legs with later spread to proximal muscles. MRI shows the early involvement of peroneal muscles followed by tibialis anterior, gastrocnemius and soleus muscles<sup>80,82</sup>. CK is usually slightly elevated.

The first causative variants in *DES* were identified in 1998<sup>103</sup>. *DES* encodes desmin, a protein of the intermediate filament connecting Z-band with the plasmalemma and the nucleus<sup>104</sup>. As suggested by a recent study, desmin forms seeding-competent amyloid that is toxic to myofi-

bers and disease-causing mutations enhance the amyloid formation<sup>105</sup>. Most patients have a dominant disease with onset in early adulthood but a later onset is possible<sup>106</sup>. Rare cases with a recessive, more severe, form have been reported<sup>107</sup>. Dominant cardiomyopathy without skeletal muscle disease, scapuloperoneal and other phenotypes, due to the increasing number of causative variants identified, are also reported<sup>108-112</sup>.

#### *Alpha-B crystallin-mutated distal myopathy – CRYAB*

In 1998, Vicart and colleagues identified the first causative variant in the *CRYAB* gene causing a myopathy with accumulation of aggregates of desmin<sup>113</sup>. In 2003, Selcen et al described patients with a generalized proximal and distal myopathy affecting also the cardiac and respiratory function and carrying mutations in *CRYAB*<sup>114D</sup>. In 2010 and in 2012, two studies identified patients with *CRYAB* mutations and a distal adult-onset myofibrillar myopathy<sup>115,116</sup>. *CRYAB*-related distal myopathy mainly involves the anterior part of the distal leg at the early stage and progresses with a milder proximal weakness. Cataracts are the hallmark and dysphagia, dysphonia, respiratory failure, and cardiomyopathy may be associated. Muscle MRI shows fatty degenerative changes in tibialis anterior, gastrocnemius medialis muscles and vastus muscles<sup>82,115,117,118</sup>.

*CRYAB* encodes alpha-B-crystallin, also called HSPB5, a member of the small heat-shock protein family, a molecular chaperone that interacts with desmin in the assembly of intermediate filaments<sup>119-122</sup>.

Causative *CRYAB* variants also cause a dominant dilated cardiomyopathy, congenital cataract (dominant and recessive) and a more severe, usually recessive myopathy (fatal infantile hypertonic myofibrillar myopathy)<sup>123-127</sup>.

## **Early adult onset distal myopathies**

#### *Miyoshi myopathy – DYSF*

Miyoshi and colleagues first described patients in the sixties with early adult-onset weakness, myalgia and atrophy in calf muscles<sup>128</sup>. Serum creatine kinase (CK) is highly elevated already in the early stages of the disease or even in presymptomatic patients. Muscle imaging shows marked involvement of posterior lower legs. Muscle biopsy shows myopathic changes with necrotic fibers in the calf muscles and inflammation is a common finding.

Dysferlin (*DYSF*) as causative gene with biallelic recessive mutations was identified in 1998<sup>2</sup>. Dysferlin is a ubiquitous transmembrane protein with a high skeletal muscle expression. The protein most probably acts

in calcium-mediated sarcolemmal fusion events and re-sealing<sup>129-131</sup>. Dysferlin expression by immunostaining or western blot (even from blood leucocytes) is useful in the diagnostic process, although the protein can be also secondarily reduced<sup>132,133</sup>.

Myoshi myopathy and LGMDR2 Dysferlin-related (previously LGMD2B), one of the most common LGMD form in several countries<sup>4,134,135</sup>, are allelic diseases with overlapping symptoms and signs<sup>136,137</sup>. LGMD patients have a more proximal involvement at the onset but, after 20 years of disease progression, the two phenotypes usually merge as dysferlinopathies<sup>138-140</sup>.

#### *Recessive distal titinopathy – TTN*

Some nonsense, small indels causing a frameshift or splice site variants in the last and second last exons of *TTN*, initially also thought to cause dominant TMD because of dominant-looking pedigrees, later proved to be recessive<sup>141-145</sup>. The presence of second causative variants *in trans* explains the novel entity of early/juvenile onset recessive distal titinopathy, a more severe condition than the late onset TMD<sup>141-143</sup>. In some families, multiple second causative variants segregating with the disease would mimic the presence of a dominant inheritance, making the diagnosis even more complex<sup>141,142,146</sup>.

The complexity of *TTN* gene may result in elusive variants not identified on DNA by the traditional pipelines<sup>147</sup>. Second tier tests, such as copy number variant (CNV) analysis and RNA sequencing, contribute to identify unrecognized pathogenic variants<sup>148-152</sup>.

#### *Distal myopathy with rimmed vacuoles (Nonaka or GNE myopathy) – GNE*

Independently described by Nonaka et al. and by Argov and Yarom, the *GNE* distal myopathy is a rimmed vacuolar recessive myopathy with an early adult onset<sup>153,154</sup>. It first affects the anterior compartment of lower legs and thigh hamstring muscles with sparing of the quadriceps, but the progression is rather severe, and half of the patients loose ambulation within 10 years. Serum creatine kinase is mildly elevated and muscle histopathology is characterized by rimmed vacuoles.

The causative gene (*GNE*) was identified in 2001<sup>155</sup> and, since then, patients have been reported worldwide. *GNE* encodes an epimerase-kinase enzyme involved in the sialic acid biosynthesis. Glycoproteins and glycolipids located in the membrane often undergo a sialic acid modification that seems to be crucial for their function<sup>156</sup>. Nevertheless, in a recent study, no consistent major change in sialylation has been observed comparing patients and matched control samples, suggesting that the pathophysiology of the disease is still unclear<sup>157</sup>.

More than 180 variants are currently known and founder mutations first reported from Middle East and Japan have been described in many populations<sup>158-163</sup>. *GNE* is susceptible to Alu-mediated recombination, and copy number variants (CNV) have been reported suggesting the utility of second-tier tests in case of an uninformative sequencing analysis aiming at the identification of single nucleotide variants<sup>164-167</sup>. Moreover, a vast clinical heterogeneity, only partly explained by the *GNE* genotype, is observed in families with *GNE* mutations<sup>160,168-170</sup>.

Sialuria is an allelic dominant metabolic disease characterized by the accumulation of N-acetylneuraminic acid (NeuAc) due to missense variants in *GNE*<sup>171</sup>.

#### *Distal ABD-filaminopathy – FLNC*

A large Australian family with a dominant, adult-onset, slowly progressive distal myopathy was described in 2005 by Williams and colleagues<sup>172</sup>. In a second Italian family with otherwise similar phenotype reported by Duff et al. cardiac involvement was also present<sup>173</sup>. Weakness of handgrip is the usual presentation followed by calf muscle plantar flexion weakness. The progression is slow, and patients remain ambulant. CK is normal or mildly elevated, and muscle MRI shows fatty replacement in posterior compartment of lower legs. Histopathology is unspecific myopathic without vacuoles or myofibrillar abnormalities.

Combining linkage data and resequencing of candidate genes in these two families, two different missense changes in the N-terminal actin-binding domain (ADB) of *FLNC* were identified<sup>173</sup>. The *FLNC* gene encodes filamin, an actin ligand that plays an important role in mechanical stabilization, mechanosensation and intracellular signaling through a large network of interactors<sup>174,175</sup>. Mutations in other parts of the gene may cause late onset myofibrillar myopathy with generalized weakness and cardiomyopathy<sup>176-178</sup>. After the gene identification in 2011, novel *FLNC* causative variants have been identified, expanding the spectrum of *FLNC*-related myopathies<sup>179-181</sup>.

Recent findings suggest a more complex genotype-phenotype correlation. A missense variant, p.M222V, in the N-terminal actin-binding domain, causing a distal myofibrillar myopathy, has been reported<sup>182</sup>. Another missense change, p.C203Y, has been recently found to cause an upper limb distal myopathy with nemaline bodies<sup>183</sup>.

#### *DNAJB6 distal myopathy – DNAJB6*

The disease was originally reported by Servidei and colleagues in a large Italian family with onset of ankle weakness between the second and sixth decades of life<sup>184</sup>, and usually progressing to proximal muscles and upper

limbs. Muscle biopsy showed dystrophic changes and rimmed vacuoles. In the Italian family, the causative variant was found in *DNAJB6*, in a different locus from the one initially reported<sup>185</sup>. *DNAJB6* encodes a ubiquitously expressed member of the DNAJ/HSP40 family of co-chaperones<sup>119,186</sup>. Mutations in *DNAJB6*, specifically in the G/F domain, cause more often a proximal myopathy (LGMD1D)<sup>187-193</sup>. Recently, a form of *DNAJB6*-related distal calf-predominant myopathy has been reported in patients with particular mutations in the N-terminal J-domain<sup>194</sup>.

#### *Rimmed vacuolar neuromyopathy – HSPB8*

Ghaoui and colleagues reported two families with a dominant *HSPB8*-related disease showing early adult neurogenic leg weakness and progressing towards a distal and proximal myofibrillar and rimmed vacuolar myopathy in the later stage of the disease<sup>195</sup>. EMG revealed denervation in the distal lower limbs and myopathic proximal changes. MRI of the lower limb muscles showed first diffuse neurogenic changes in gastrocnemius, deep toe flexors, and peroneus with later fatty replacement in proximal thigh and lower legs muscles.

The *HSPB8* gene encodes the small heat-shock protein-beta 8, acting as stress protein with a chaperone-like activity and part of the chaperone-assisted selective autophagy (CASA) complex<sup>119,196</sup>. *HSPB8* missense variants had been previously associated with distal hereditary motor neuropathy 2A (dHMN2A) and Charcot-Marie-Tooth disease (CMT2L)<sup>197-201</sup>. The myofibrillar myopathy with aggregates and rimmed vacuoles mimics the histopathological changes seen in myopathies caused by defects in *BAG3* and *DNAJB6*<sup>202,203</sup>.

Later other families with a combined neuromuscular disorder, encompassing dHMN and MFH have been described<sup>204</sup>. In one family decrease of *TARDBP* mRNA levels causing a consistent alteration of TDP-43-dependent splicing was reported<sup>204</sup>. Recently, a novel *HSPB8* variant has been found in a patient with limb-girdle myopathy without associated neuropathy<sup>205</sup>.

#### *ANO5 distal muscular dystrophy – ANO5*

Distal anoctaminopathy has an age of onset in early/mid adulthood (18-40 years)<sup>206,207</sup>. Early manifestations include difficulties in sport activity and in walking on tip-toes but often the clinical presentation is mild, or the disease does not even result in overt clinical signs. The early stage hypertrophy of calf muscles progresses into muscle atrophy<sup>208</sup>. At a later stage, proximal muscle weakness and wasting is observed. Typically, the cardiac muscle is spared. CK levels are usually highly elevated (over 10 times the upper limits). Non-specific myopathic changes with scattered necrotic fibers are observed in the muscle biopsy.

The disease is due to bi-allelic causative variants in the *ANO5* gene, encoding for anoctamin-5, a putative cytoplasmic calcium-activated chloride channel, with a possible role in membrane fusion and repair<sup>209,210</sup>. The more common phenotype of bi-allelic variants in *ANO5* is late onset proximal (LGMDR12)<sup>206,207,211-214</sup>. Variants causing *ANO5*-related recessive anoctaminopathies mostly result in a reduced protein expression and missense changes likely destabilize the protein, causing its degradation<sup>215,216</sup>. We still lack a clear genotype-phenotype correlation explaining the high intrafamilial and interfamilial clinical variability observed, also considering that female patients often have a milder disease than males<sup>206,212,217-221</sup>.

A dominant form of gnathodiaphyseal dysplasia is (GDD) an allelic disorder caused by *ANO5* missense variants in heterozygosity<sup>222,223</sup>. The pathomechanism of the *ANO5*-related GDD is still unclear. However, the protein seems to have an important role in the embryonic development and most probably in the osteoblast differentiation<sup>223</sup>.

#### *RYR1 mutated calf predominant distal myopathy – RYR1*

A very mild dominant distal myopathy with preferential fatty degeneration of medial gastrocnemius, clearly shown by muscle MRI, has been recently reported in one Italian and two Finnish families<sup>224</sup>. Some patients exhibit toe walking in the childhood with spontaneous remission. In adulthood, patients complain of exercise myalgia in the calves, and show 5-10 fold elevated CK. No limitation of walking was present even in elderly patients. Muscle biopsy reveals core pathology. Three different *RYR1* mutations were identified in different parts of the gene, which encodes ryanodine receptor 1, a calcium release channel of the sarcoplasmic reticulum that, together with sarcolemmal voltage-gated calcium channels (DHPR), is responsible for the excitation-contraction coupling.

Dominant and recessive mutations in the *RYR1* gene present with a multitude of phenotypes including malignant hyperthermia (MH) susceptibility and congenital central core disease (CCD), centronuclear myopathy, multiminicore myopathy, congenital fibre type disproportion, axial myopathy, King-Denborough syndrome, atypical periodic paralysis and exertional rhabdomyolysis/myalgia<sup>225-235</sup>. A childhood-onset distal myopathy presenting with hand stiffness and facial weakness has been associated to bi-allelic *RYR1* variants<sup>236</sup>.

## **Early-childhood onset distal myopathies**

#### *Early onset distal myopathy (Laing myopathy) – MYH7*

Laing myopathy was the first distal myopathy with established genetic linkage<sup>237</sup>. The onset is in early child-

hood with the ankle dorsiflexor and toe extensor (hanging big toe) weakness and the disease has a slow progression. Severe forms develop scoliosis and involves proximal, neck and facial muscles. CK levels are normal or mildly elevated. The most consistent histopathology is hypotrophy of type 1 slow fibers, often combined with core/minicore lesions<sup>238</sup>. Muscle MRI shows the involvement of anterior compartment lower leg muscles and, eventually, of the sartorius, with relative sparing of the lateral gastrocnemius muscle and rectus femoris<sup>239-242</sup>.

In 2004 the causative variant was identified in the *MYH7* gene encoding the beta heavy chain of myosin<sup>243</sup>. Since then, a large number of causative variants in the tail of the protein were reported, with a large proportion (30%) of re-occurring de novo mutations masking the dominant effect of the variants<sup>244-248</sup>. Causative variants in the head and neck domains at the N-terminal of the protein have been mainly associated with hypertrophic cardiomyopathy (without skeletal muscle involvement)<sup>249-251</sup>. Variants in the ultimate C-terminal region most often result in other skeletal myopathies (hyaline body myopathy) with or without cardiac involvement<sup>252,253</sup>. Rare recessive forms of *MYH7*-related myopathy have been reported<sup>254-256</sup>.

#### *Early onset distal myopathies with nebulin defect – NEB*

Bi-allelic, mainly missense, variants in *NEB* gene may result in an early-onset distal myopathy with a predominant weakness of extensor muscles of feet and later hands<sup>257,258</sup>. The progression is very slow and adult patients do not have major disability.

Muscle imaging shows a selective fatty degeneration in the anterior tibial muscles, EMG is myopathic and CK is normal or mildly elevated. Scattered and grouped atrophic fibers (that can be misinterpreted as neurogenic changes) are detectable in the biopsy of affected muscle without rods on light microscopy<sup>258,259</sup>. Small rods associated with Z-disks may be present on electron microscopy<sup>259</sup>.

A large in-frame deletion, dominantly inherited in a three-generation family with a distal nemaline rod/cap myopathy, was recently described<sup>260</sup>. The in-frame deletion results in a protein of reduced size with a dominant-negative effect<sup>260</sup>. Patients present with foot drop in childhood and the disease progresses with the involvement of distal upper limbs. CK can be slightly elevated, EMG is myopathic and muscle MRI shows fatty degeneration of the anterior compartment lower leg muscles. A large heterozygous de novo deletion in young patient with asymmetric distal and facial weakness has just been identified confirming the dominant effect of an abnormal protein (submitted).

The 183-exon *NEB* gene encodes nebulin, a protein of 600-900 kDa that regulates the length of actin fila-

ments<sup>261,262</sup>. Causative variants in *NEB* (mainly nonsense, out-of-frame indels or copy number variants, and splicing variants) are the most common cause of congenital nemaline myopathy<sup>263,264</sup>. Additional allelic diseases are core rod myopathy, and fetal akinesia/lethal multiple pterygium syndrome<sup>259,265,266</sup>.

Copy number variant (CNV) analysis and RNA sequencing are essential to identify possible elusive pathogenic *NEB* variants<sup>148-150,267,268</sup>.

#### *Early onset ADSSL distal myopathy – ADSSL*

In 2016, Park and colleagues reported two unrelated Korean families with an autosomal recessive adolescent-onset distal myopathy with facial muscle weakness, mild CK elevation and rimmed vacuoles in the muscular biopsy<sup>269,270</sup>. Two different variants in the *ADSSL* gene were identified by exome sequencing. The *ADSSL* gene encodes the muscle isozyme of adenylosuccinate synthase, the enzyme catalysing the initial reaction in the conversion of inosine monophosphate (IMP) to adenosine monophosphate (AMP)<sup>271,272</sup>. Two following studies identified novel Korean and non-Korean (Turkish and Indian) patients, confirming the gene-disease association<sup>273,274</sup>. Most patients presented with a distal myopathy with onset in childhood or adolescence progressing to involve weakness of proximal muscles in early adulthood. However, one patient, homozygous for a missense variant, shows a proximal myopathy with contractures and muscle atrophy, expanding the *ADSSL*-related spectrum of phenotypes<sup>274</sup>.

#### *Early onset distal myopathy with KLHL9 mutations – KLHL9*

Cirak and colleagues described a German family with an autosomal distal weakness caused by a heterozygous variant in the *KLHL9* gene<sup>275</sup>. Despite extensive later studies, this gene has not been confirmed in any other myopathy families.

## **Other myopathies and dystrophies with distal weakness**

#### *Distal myopathy with caveolin defect – CAV3*

In 2002, Tateyama and colleagues described a form of sporadic distal myopathy caused by an heterozygous missense variant in *CAV3* gene<sup>276</sup>. Since then, additional patients and further causative variants have been reported<sup>277,278</sup>. Onset is in early adulthood, muscle atrophy and weakness are often limited to the small muscles of the hands and feet. Other features included calf hypertrophy, pes cavus, myalgias, slightly increased serum CK. EMG studies show a myopathic pattern and histological find-



ings include nonspecific myopathic changes<sup>278,279</sup>. *CAV3* expression can be reduced.

Variants in *CAV3* can also cause an isolated hyperkemia or a rippling muscle disease<sup>280-285</sup> and even cardiac phenotypes (hypertrophic cardiomyopathy and long QT syndrome)<sup>286,287</sup>. Some patients with *CAV3* related myopathy have been previously described as LGMD1C patients<sup>288</sup>.

#### *DNM2* related distal myopathy – *DNM2*

*DNM2*-related myopathy is an autosomal dominant slowly progressive centronuclear myopathy characterized by the presence of centrally located nuclei in a several muscle fibres<sup>289</sup>. The clinical onset is usually in childhood or early adulthood<sup>290</sup>. The distal muscle weakness is marked although facial weakness is the clinical lead to diagnosis<sup>291-300</sup>. More severe forms, clinically resembling myotubular myopathy, have been described<sup>301</sup>. MRI studies shows fatty infiltration of the calf muscles<sup>302</sup>. Electromyography may show a mix pattern with myopathic and neuropathic changes.

*DNM2* encodes dynamin 2, a ubiquitously expressed GTPase that is involved in endocytosis and intracellular trafficking<sup>303-306</sup>. Dynamin 2 interacts with actin and has an active role in regulating microtubule networks and in centrosome function<sup>307</sup>. *DNM2* mutations can also cause an intermediate or axonal CMT disease with and without cataracts<sup>308</sup>. A lethal congenital syndrome associating akinesia, joint contractures, hypotonia, skeletal abnormalities, and brain and retinal haemorrhages has been observed in three consanguineous families with a missense variant (p.Phe379Val) in homozygosity<sup>309</sup>.

### Differential diagnostics

A long range of other myopathies needs to be considered in the differential diagnostics since they may show prominent distal weakness and/or atrophy:

- Facioscapulohumeral muscular dystrophy;
- Myotonic dystrophy type1;
- HMERF titinopathy (i.e. p.C31712R mutation);
- Scapuloperoneal syndromes (FHL-1, *TRIM32*,...);
- Other nemaline and rod-core myopathies (*TPM2*, *ACTA1*,...);
- Inclusion body myositis;
- Telethoninopathy;
- Glycogenoses: brancher and debrancher enzyme defects;
- Lipidosis in *PNPLA2* mutated disease;
- Mitochondrial distal myopathy (*POLG1*);
- Nephropathic cystinosis;
- Amyloid myopathy (myeloma induced).

### Conclusions

Despite the huge developments in the last 20 years to uncover the genetic cause of distal myopathy, some families and patients still remain without a final diagnosis. The introduction of long read sequencing and RNA sequencing in clinical care and the constitution of large international consortia will most probably further increase the diagnostic rate<sup>310-316</sup>.

The reason for some genetic defects to have preference for the distal limb muscles in causing loss of muscle tissue is unclear and understanding the molecular background for this preference may also harbour insight for therapeutic opportunities.

Considering the crucial advancements in the last decade, we can look forward optimistically to the upcoming decade. We will most probably identify an increasing number of digenic diseases and of genetic and non-genetic modifiers influencing the phenotype. The next challenge is to translate the genetic and molecular advancements in clinics, thereby contributing to the development of a personalized medicine aiming at providing a tailored approach to each patient with a distal myopathy<sup>317,318</sup>.

### References

- 1 Gowers WR. A lecture on myopathy and a distal form: delivered at the National Hospital for the Paralysed and Epileptic. *Br Med J* 1902;2:89-92. <https://doi.org/10.1136/bmj.2.2167.89>
- 2 Liu J, Aoki M, Illa I, et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. *Nat Genet* 1998;20:31-6. <https://doi.org/10.1038/1682>
- 3 Evila A, Arumilli M, Udd B, et al. Targeted next-generation sequencing assay for detection of mutations in primary myopathies. *Neuromuscul Disord* 2016;26:7-15. <https://doi.org/10.1016/j.nmd.2015.10.003>
- 4 Nallamilli BRR, Chakravorty S, Kesari A, et al. Genetic landscape and novel disease mechanisms from a large LGMD cohort of 4656 patients. *Ann Clin Transl Neurol* 2018;5:1574-87. <https://doi.org/10.1002/acn3.649>
- 5 Savarese M, Di Fruscio G, Torella A, et al. The genetic basis of undiagnosed muscular dystrophies and myopathies: results from 504 patients. *Neurology* 2016;87:71-6. <https://doi.org/10.1212/WNL.0000000000002800>
- 6 Ankala A, da Silva C, Gualandi F, et al. A comprehensive genomic approach for neuromuscular diseases gives a high diagnostic yield. *Ann Neurol* 2015;77:206-14. <https://doi.org/10.1002/ana.24303>
- 7 Ghaoui R, Cooper ST, Lek M, et al. Use of whole-exome sequencing for diagnosis of limb-girdle muscular dystrophy: outcomes and lessons learned. *JAMA Neurol* 2015;72:1424-32. <https://doi.org/10.1001/jamaneurol.2015.2274>
- 8 Benarroch L, Bonne G, Rivier F, et al. The 2020 version of the

- gene table of neuromuscular disorders (nuclear genome). *Neuromuscul Disord* 2019;29:980-1018. <https://doi.org/10.1016/j.nmd.2019.10.010>
- <sup>9</sup> Welander L. Myopathia distalis tarda hereditaria; 249 examined cases in 72 pedigrees. *Acta Med Scand* 1951(Suppl);265:1-124 (<https://www.ncbi.nlm.nih.gov/pubmed/14894174>). Published 1951/01/01).
- <sup>10</sup> Hackman P, Sarparanta J, Lehtinen S, et al. Welander distal myopathy is caused by a mutation in the RNA-binding protein TIA1. *Ann Neurol* 2013;73:500-9. <https://doi.org/10.1002/ana.23831>
- <sup>11</sup> Klar J, Sobol M, Melberg A, et al. Welander distal myopathy caused by an ancient founder mutation in TIA1 associated with perturbed splicing. *Hum Mut* 2013;34:572-7. <https://doi.org/10.1002/humu.22282>
- <sup>12</sup> Tian Q, Streuli M, Saito H, Schlossman SF, Anderson P. A polyadenylate binding protein localized to the granules of cytolytic lymphocytes induces DNA fragmentation in target cells. *Cell* 1991;67:629-39. [https://doi.org/10.1016/0092-8674\(91\)90536-8](https://doi.org/10.1016/0092-8674(91)90536-8)
- <sup>13</sup> Eisinger-Mathason TS, Andrade J, Groehler AL, et al. Codependent functions of RSK2 and the apoptosis-promoting factor TIA-1 in stress granule assembly and cell survival. *Mol Cell* 2008;31:722-36. <https://doi.org/10.1016/j.molcel.2008.06.025>
- <sup>14</sup> Forch P, Puig O, Kedersha N, et al. The apoptosis-promoting factor TIA-1 is a regulator of alternative pre-mRNA splicing. *Mol Cell* 2000;6:1089-98. [https://doi.org/10.1016/s1097-2765\(00\)00107-6](https://doi.org/10.1016/s1097-2765(00)00107-6)
- <sup>15</sup> Lee Y, Jonson PH, Sarparanta J, et al. TIA1 variant drives myodegeneration in multisystem proteinopathy with SQSTM1 mutations. *J Clin Invest* 2018;128:1164-77. <https://doi.org/10.1172/JCI97103>
- <sup>16</sup> Udd B, Hakamies L, Partanen J, et al. Tibial muscular dystrophy: late adult-onset distal myopathy in 66 Finnish patients. *Arch Neurol* 1993;50:604-8. <https://doi.org/10.1001/archneur.1993.00540060044015>
- <sup>17</sup> Hackman P, Vihola A, Haravuori H, et al. Tibial muscular dystrophy is a titinopathy caused by mutations in TTN, the gene encoding the giant skeletal-muscle protein titin. *Am J Hum Genet* 2002;71:492-500. <https://doi.org/10.1086/342380>
- <sup>18</sup> Pollazzon M, Suominen T, Penttila S, et al. The first Italian family with tibial muscular dystrophy caused by a novel titin mutation. *J Neurol* 2010;257:575-9. <https://doi.org/10.1007/s00415-009-5372-3>
- <sup>19</sup> Van den Bergh PYK, Bouquiaux O, Verellen C, et al. Tibial muscular dystrophy in a Belgian family. *Ann Neurol* 2003;54:248-51. <https://doi.org/10.1002/ana.10647>
- <sup>20</sup> Bang ML, Centner T, Fornoff F, et al. The complete gene sequence of titin, expression of an unusual approximately 700-kDa titin isoform, and its interaction with obscurin identify a novel Z-line to I-band linking system. *Circ Res* 2001;89:1065-72. <https://doi.org/10.1161/hh2301.100981>
- <sup>21</sup> Charton K, Sarparanta J, Vihola A, et al. CAPN3-mediated processing of C-terminal titin replaced by pathological cleavage in titinopathy. *Hum Mol Genet* 2015;24:3718-31. <https://doi.org/10.1093/hmg/ddv116>
- <sup>22</sup> Sarparanta J, Blandin G, Charton K, et al. Interactions with M-band titin and calpain 3 link myospryn (CMYA5) to tibial and limb-girdle muscular dystrophies. *J Biol Chem* 2010;285:30304-15. <https://doi.org/10.1074/jbc.M110.108720>
- <sup>23</sup> Savarese M, Jonson PH, Huovinen S, et al. The complexity of titin splicing pattern in human adult skeletal muscles. *Skelet Muscle* 2018;8:11. <https://doi.org/10.1186/s13395-018-0156-z>
- <sup>24</sup> Uapinyoying P, Goecks J, Knoblach SM, et al. A long-read RNA-seq approach to identify novel transcripts of very large genes. *Genome Res* 2020;30:885-97. <https://doi.org/10.1101/gr.259903.119>
- <sup>25</sup> Savarese M, Sarparanta J, Vihola A, Udd B, Hackman P. Increasing role of titin mutations in neuromuscular disorders. *J Neuromuscul Dis* 2016;3:293-308. <https://doi.org/10.3233/JND-160158>
- <sup>26</sup> Hackman P, Udd B, Bonnemann CG, et al. Titinopathy database C. 219<sup>th</sup> ENMC International Workshop Titinopathies International database of titin mutations and phenotypes, Heemskerk, The Netherlands, 29 April-1 May 2016. *Neuromuscul Disord* 2017;27:396-407. <https://doi.org/10.1016/j.nmd.2017.01.009>
- <sup>27</sup> Palmio J, Evila A, Chapon F, et al. Hereditary myopathy with early respiratory failure: occurrence in various populations. *J Neurol Neurosurg Psychiatry* 2014;85:345-53. <https://doi.org/10.1136/jnnp-2013-304965>
- <sup>28</sup> Palmio J, Leonard-Louis S, Sacconi S, et al. Expanding the importance of HMERF titinopathy: new mutations and clinical aspects. *J Neurol* 2019;266:680-90. <https://doi.org/10.1007/s00415-019-09187-2>
- <sup>29</sup> Tasca G, Udd B. Hereditary myopathy with early respiratory failure (HMERF): still rare, but common enough. *Neuromuscul Disord* 2018;28:268-76. <https://doi.org/10.1016/j.nmd.2017.12.002>
- <sup>30</sup> Savarese M, Vihola A, Oates EC, et al. Genotype-phenotype correlations in recessive titinopathies. *Genet Med* 2020;Aug 11. <https://doi.org/10.1038/s41436-020-0914-2>
- <sup>31</sup> Oates EC, Jones KJ, Donkervoort S, et al. Congenital titinopathy: comprehensive characterization and pathogenic insights. *Ann Neurol* 2018;83:1105-24. <https://doi.org/10.1002/ana.25241>
- <sup>32</sup> Herman DS, Lam L, Taylor MR, et al. Truncations of titin causing dilated cardiomyopathy. *N Engl J Med* 2012;366:619-28. <https://doi.org/10.1056/NEJMoa1110186>
- <sup>33</sup> Itoh-Satoh M, Hayashi T, Nishi H, et al. Titin mutations as the molecular basis for dilated cardiomyopathy. *Biochem Biophys Res Commun* 2002;291:385-93. <https://doi.org/10.1006/bbrc.2002.6448>
- <sup>34</sup> Feit H, Silbergleit A, Schneider LB, et al. Vocal cord and pharyngeal weakness with autosomal dominant distal myopathy: clinical description and gene localization to 5q31. *Am J Hum Gen* 1998;63:1732-42. <https://doi.org/10.1086/302166>
- <sup>35</sup> Senderek J, Garvey SM, Krieger M, et al. Autosomal-dominant distal myopathy associated with a recurrent missense mutation in the gene encoding the nuclear matrix protein, matrin 3. *Am J Hum Genet* 2009;84:511-8. <https://doi.org/10.1016/j.ajhg.2009.03.006>

- <sup>36</sup> Muller TJ, Kraya T, Stoltenburg-Didinger G, et al. Phenotype of matrin-3-related distal myopathy in 16 German patients. *Ann Neurol* 2014;76:669-80. <https://doi.org/10.1002/ana.24255>
- <sup>37</sup> Barp A, Malfatti E, Metay C, et al. The first French case of MATR3-related distal myopathy: clinical, radiological and histopathological characterization. *Rev Neurol (Paris)* 2018;174:752-5. <https://doi.org/10.1016/j.neurol.2017.08.004>
- <sup>38</sup> Kraya T, Schmidt B, Muller T, et al. Impairment of respiratory function in late-onset distal myopathy due to MATR3 Mutation. *Muscle Nerve* 2015;51:916-8. <https://doi.org/10.1002/mus.24603>
- <sup>39</sup> Mensch A, Kraya T, Koester F, et al. Whole-body muscle MRI of patients with MATR3-associated distal myopathy reveals a distinct pattern of muscular involvement and highlights the value of whole-body examination. *J Neurol* 2020;267:2408-20. <https://doi.org/10.1007/s00415-020-09862-9>
- <sup>40</sup> Belgrader P, Dey R, Berezney R. Molecular cloning of matrin 3. A 125-kilodalton protein of the nuclear matrix contains an extensive acidic domain. *J Biol Chem* 1991;266:9893-9. <https://www.ncbi.nlm.nih.gov/pubmed/2033075>. Published 1991/05/25.
- <sup>41</sup> Nakayasu H, Berezney R. Nuclear matrins: identification of the major nuclear matrix proteins. *PNAS* 1991;88:10312-6. <https://doi.org/10.1073/pnas.88.22.10312>
- <sup>42</sup> Johnson JO, Pioro EP, Boehringer A, et al. Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. *Nat Neurosci* 2014;17:664-6. <https://doi.org/10.1038/nn.3688>
- <sup>43</sup> Savarese M, Palmio J, Poza JJ, et al. Actininopathy: a new muscular dystrophy caused by ACTN2 dominant mutations. *Ann Neurol* 2019;85:899-906. <https://doi.org/10.1002/ana.25470>
- <sup>44</sup> Tiso N, Majetti M, Stanchi F, et al. Fine mapping and genomic structure of ACTN2, the human gene coding for the sarcomeric isoform of alpha-actinin-2, expressed in skeletal and cardiac muscle. *Biochem Biophys Res Commun* 1999;265:256-9. <https://doi.org/10.1006/bbrc.1999.1661>
- <sup>45</sup> Young P, Ferguson C, Banuelos S, et al. Molecular structure of the sarcomeric Z-disk: two types of titin interactions lead to an asymmetrical sorting of alpha-actinin. *EMBO J* 1998;17:1614-24. <https://doi.org/10.1093/emboj/17.6.1614>
- <sup>46</sup> Gupta V, Discenza M, Guyon JR, et al. alpha-Actinin-2 deficiency results in sarcomeric defects in zebrafish that cannot be rescued by alpha-actinin-3 revealing functional differences between sarcomeric isoforms. *FASEB journal: official publication of the Federation of American Societies for Experimental Biology* 2012;26:1892-908. <https://doi.org/10.1096/fj.11-194548>
- <sup>47</sup> Ribeiro Ede A, Jr., Pinotsis N, Ghisleni A, et al. The structure and regulation of human muscle alpha-actinin. *Cell* 2014;159:1447-60. <https://doi.org/10.1016/j.cell.2014.10.056>
- <sup>48</sup> Lornage X, Romero NB, Grosogeat CA, et al. ACTN2 mutations cause "Multiple structured Core Disease" (MsCD). *Acta Neuropathol* 2019;137:501-19. <https://doi.org/10.1007/s00401-019-01963-8>
- <sup>49</sup> Haywood NJ, Wolny M, Rogers B, et al. Hypertrophic cardiomyopathy mutations in the calponin-homology domain of ACTN2 affect actin binding and cardiomyocyte Z-disc incorporation. *Biochem J* 2016;473:2485-93. <https://doi.org/10.1042/BCJ20160421>
- <sup>50</sup> Mohapatra B, Jimenez S, Lin JH, et al. Mutations in the muscle LIM protein and alpha-actinin-2 genes in dilated cardiomyopathy and endocardial fibroelastosis. *Mol Genet Metab* 2003;8:207-15. [https://doi.org/10.1016/s1096-7192\(03\)00142-2](https://doi.org/10.1016/s1096-7192(03)00142-2)
- <sup>51</sup> Chiu C, Bagnall RD, Ingles J, et al. Mutations in alpha-actinin-2 cause hypertrophic cardiomyopathy: a genome-wide analysis. *J Am Coll Cardio* 2010;55:1127-35. <https://doi.org/10.1016/j.jacc.2009.11.016>
- <sup>52</sup> Girolami F, Iascone M, Tomberli B, et al. Novel alpha-actinin 2 variant associated with familial hypertrophic cardiomyopathy and juvenile atrial arrhythmias: a massively parallel sequencing study. *Circ Cardiovasc Genet* 2014;7:741-50. <https://doi.org/10.1161/CIRCGENETICS.113.000486>
- <sup>53</sup> Bagnall RD, Molloy LK, Kalman JM, et al. Exome sequencing identifies a mutation in the ACTN2 gene in a family with idiopathic ventricular fibrillation, left ventricular noncompaction, and sudden death. *BMC Med Genet* 2014;15:99. <https://doi.org/10.1186/s12881-014-0099-0>
- <sup>54</sup> Edstrom L, Thornell LE, Eriksson A. A new type of hereditary distal myopathy with characteristic sarcoplasmic bodies and intermediate (skeletal) filaments. *J Neurol Sci* 1980;47:171-90. [https://doi.org/10.1016/0022-510x\(80\)90002-7](https://doi.org/10.1016/0022-510x(80)90002-7)
- <sup>55</sup> Olive M, Engvall M, Ravenscroft G, et al. Myoglobinopathy is an adult-onset autosomal dominant myopathy with characteristic sarcoplasmic inclusions. *Nat Commun* 2019;10:1396. <https://doi.org/10.1038/s41467-019-09111-2>
- <sup>56</sup> Durmus H, Laval SH, Deymeer F, et al. Oculopharyngodistal myopathy is a distinct entity: Clinical and genetic features of 47 patients. *Neurology* 2011;76:227-35. <https://doi.org/10.1212/WNL.0b013e318207b043>
- <sup>57</sup> Lu H, Luan X, Yuan Y, et al. The clinical and myopathological features of oculopharyngodistal myopathy in a Chinese family. *Neuropathology* 2008;28:599-603. <https://doi.org/10.1111/j.1440-1789.2008.00924.x>
- <sup>58</sup> Ishiura H, Shibata S, Yoshimura J, et al. Noncoding CGG repeat expansions in neuronal intranuclear inclusion disease, oculopharyngodistal myopathy and an overlapping disease. *Nat Genet* 2019;51:1222-32. <https://doi.org/10.1038/s41588-019-0458-z>
- <sup>59</sup> Saito R, Shimizu H, Miura T, et al. Oculopharyngodistal myopathy with coexisting histology of systemic neuronal intranuclear inclusion disease: clinicopathologic features of an autopsied patient harboring CGG repeat expansions in LRP12. *Acta Neuropathol Commun*. 2020;8:75. <https://doi.org/10.1186/s40478-020-00945-2>
- <sup>60</sup> Sone J, Mitsuhashi S, Fujita A, et al. Long-read sequencing identifies GGC repeat expansions in NOTCH2NLC associated with neuronal intranuclear inclusion disease. *Nat Genet* 2019;51:1215-21. <https://doi.org/10.1038/s41588-019-0459-y>

- <sup>61</sup> Deng J, Yu J, Li P, et al. Expansion of GGC repeat in GIPC1 is associated with oculopharyngodistal myopathy. *Am J Hum Genet* 2020;106:793-804. <https://doi.org/10.1016/j.ajhg.2020.04.011>
- <sup>62</sup> Di Blasi C, Moghadaszadeh B, Ciano C, et al. Abnormal lysosomal and ubiquitin-proteasome pathways in 19p13.3 distal myopathy. *Ann Neurol* 2004;56:133-8. <https://doi.org/10.1002/ana.20158>
- <sup>63</sup> Ruggieri A, Naumenko S, Smith MA, et al. Multiomic elucidation of a coding 99-mer repeat-expansion skeletal muscle disease. *Acta Neuropathol* 2020;140:231-5. <https://doi.org/10.1007/s00401-020-02164-4>
- <sup>64</sup> Pourteymour S, Lee S, Langleite TM, et al. Perilipin 4 in human skeletal muscle: localization and effect of physical activity. *Physiol Rep* 2015;3. <https://doi.org/10.14814/phy2.12481>
- <sup>65</sup> Palmio J, Sandell S, Suominen T, et al. Distinct distal myopathy phenotype caused by VCP gene mutation in a Finnish family. *Neuromuscul Disord* 2011;21:551-5. <https://doi.org/10.1016/j.nmd.2011.05.008>
- <sup>66</sup> Ikenaga C, Findlay AR, Seiffert M, et al. Phenotypic diversity in an international Cure VCP Disease registry. *Orphanet J Rare Dis* 2020;15:267. <https://doi.org/10.1186/s13023-020-01551-0>
- <sup>67</sup> Guo X, Zhao Z, Shen H, et al. VCP myopathy: A family with unusual clinical manifestations. *Muscle Nerve* 2019;59:365-9. <https://doi.org/10.1002/mus.26389>
- <sup>68</sup> Al-Tahan S, Al-Obeidi E, Yoshioka H, et al. Novel valosin-containing protein mutations associated with multisystem proteinopathy. *Neuromuscul Disord* 2018;28:91-501. <https://doi.org/10.1016/j.nmd.2018.04.007>
- <sup>69</sup> Boland-Freitas R, Graham J, Davis M, et al. Late-onset distal myopathy of the upper limbs due to P.Ile151Val mutation in the valosin-containing protein. *Muscle Nerve* 2016;54:165-6. <https://doi.org/10.1002/mus.25073>
- <sup>70</sup> Kazamel M, Sorenson EJ, McEvoy KM, et al. Clinical spectrum of valosin containing protein (VCP)-opathy. *Muscle Nerve* 2016;54:94-9. <https://doi.org/10.1002/mus.24980>
- <sup>71</sup> Liewluck T, Milone M, Mauermann ML, et al. A novel VCP mutation underlies scapuloperoneal muscular dystrophy and dropped head syndrome featuring lobulated fibers. *Muscle Nerve* 2014;50:295-9. <https://doi.org/10.1002/mus.24290>
- <sup>72</sup> Shi Z, Hayashi YK, Mitsuhashi S, et al. Characterization of the Asian myopathy patients with VCP mutations. *Eur J Neurol* 2012;19:501-9. <https://doi.org/10.1111/j.1468-1331.2011.03575.x>
- <sup>73</sup> Papadopoulos C, Malfatti E, Anagnostou E, et al. Valosin-containing protein-related myopathy and Meige syndrome: Just a coincidence or not? *Muscle Nerve* 2019;60:e43-5. <https://doi.org/10.1002/mus.26704>
- <sup>74</sup> Watts GDJ, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. *Nature Genetics* 2004;36:377-81. <https://doi.org/10.1038/ng1332>
- <sup>75</sup> Kimonis VE, Mehta SG, Fulchiero EC, et al. Clinical studies in familial VCP myopathy associated with paget disease of bone and frontotemporal dementia. *Am J Med Genet, Part A*. 2008;146:745-57. <https://doi.org/10.1002/ajmg.a.31862>
- <sup>76</sup> Stojkovic T, Hammouda EH, Richard P, et al. Clinical outcome in 19 French and Spanish patients with valosin-containing protein myopathy associated with Paget's disease of bone and frontotemporal dementia. *Neuromuscul Disord* 2009;19:316-23. <https://doi.org/10.1016/j.nmd.2009.02.012>
- <sup>77</sup> Olivé M, Goldfarb LG, Shatunov A, et al. Refining the clinical and myopathological phenotype. *Brain* 2005;128:2315-26. <https://doi.org/10.1093/brain/awh576>
- <sup>78</sup> Péniisson-Besnier I, Talvinen K, Dumez C, et al. Myotilinopathy in a family with late onset myopathy. *Neuromuscular Disord* 2006;16:427-31. <https://doi.org/10.1016/j.nmd.2006.04.009>
- <sup>79</sup> Selcen D, Engel AG. Mutations in myotilin cause myofibrillar myopathy. *Neurology* 2004;62:1363-71. <https://doi.org/10.1212/01.wnl.0000123576.74801.75>
- <sup>80</sup> Fischer D, Clemen CS, Olive M, et al. Different early pathogenesis in myotilinopathy compared to primary desminopathy. *Neuromuscul Disord* 2006;16:361-7. <https://doi.org/10.1016/j.nmd.2006.03.007>
- <sup>81</sup> Maerkens A, Olive M, Schreiner A, et al. New insights into the protein aggregation pathology in myotilinopathy by combined proteomic and immunolocalization analyses. *Acta Neuropathol Commun* 2016;4:8. <https://doi.org/10.1186/s40478-016-0280-0>
- <sup>82</sup> Fischer D, Kley RA, Strach K, et al. Distinct muscle imaging patterns in myofibrillar myopathies. *Neurology* 2008;71:758-65. <https://doi.org/10.1212/01.wnl.0000324927.28817.9b>
- <sup>83</sup> Bugiardini E, Morrow JM, Shah S, et al. The diagnostic value of MRI pattern recognition in distal myopathies. *Front Neurol* 2018;9:456. <https://doi.org/10.3389/fneur.2018.00456>
- <sup>84</sup> Salmikangas P, van der Ven PF, Lalowski M, et al. Myotilin, the limb-girdle muscular dystrophy 1A (LGMD1A) protein, cross-links actin filaments and controls sarcomere assembly. *Hum Mol Genet* 2003;12:189-203. <https://doi.org/10.1093/hmg/ddg020>
- <sup>85</sup> Hauser MA, Horrigan SK, Salmikangas P, et al. Myotilin is mutated in limb girdle muscular dystrophy 1A. *Hum Mol Genet* 2000;9:2141-7. <https://doi.org/10.1093/hmg/9.14.2141>
- <sup>86</sup> Hauser MA, Conde CB, Kowaljow V, et al. myotilin Mutation found in second pedigree with LGMD1A. *Am J Hum Genet* 2002;71:1428-32. <https://doi.org/10.1086/344532>
- <sup>87</sup> Rudolf G, Suominen T, Penttilä S, et al. Homozygosity of the dominant myotilin c.179C>T (p.Ser60Phe) mutation causes a more severe and proximal muscular dystrophy. *J Neuromuscul Disord* 2016;3:275-81. <https://doi.org/10.3233/JND-150143>
- <sup>88</sup> Schessl J, Bach E, Rost S, et al. Novel recessive myotilin mutation causes severe myofibrillar myopathy. *Neurogenetics* 2014;15:151-6. <https://doi.org/10.1007/s10048-014-0410-4>
- <sup>89</sup> Foroud T, Pankratz N, Batchman AP, et al. A mutation in myotilin causes spheroid body myopathy. *Neurology* 2005;65:1936-40. <https://doi.org/10.1212/01.wnl.0000188872.28149.9a>



- <sup>90</sup> Goebel HH, Muller J, Gillen HW, et al. Autosomal dominant "spheroid body myopathy". *Muscle Nerve* 1978;1:14-26. <https://doi.org/10.1002/mus.880010104>
- <sup>91</sup> Griggs R, Vihola A, Hackman P, et al. Zaspopathy in a large classic late-onset distal myopathy family. *Brain* 2007;130(Pt 6):1477-84. <https://doi.org/10.1093/brain/awm006>
- <sup>92</sup> Newby R, Jamieson S, Udd B, et al. When myopathy breaks the rules: a late-onset distal presentation. *BMJ Case Rep* 2015;2015. <https://doi.org/10.1136/bcr-2015-209436>
- <sup>93</sup> Zheng J, Chen S, Chen Y, et al. A novel mutation in the PDZ-like motif of ZASP causes distal ZASP-related myofibrillar myopathy. *Neuropathology* 2017;37:45-51. <https://doi.org/10.1111/neup.12328>
- <sup>94</sup> Strach K, Reimann J, Thomas D, et al. ZASPopathy with childhood-onset distal myopathy. *J Neurol* 2012;259:1494-6. <https://doi.org/10.1007/s00415-012-6543-1>
- <sup>95</sup> Behin A, Salort-Campana E, Wahbi K, et al. Myofibrillar myopathies: state of the art, present and future challenges. *Rev Neurol (Paris)* 2015;171:715-29. <https://doi.org/10.1016/j.neurol.2015.06.002>
- <sup>96</sup> Claeys KG, Fardeau M, Schröder R, et al. Electron microscopy in myofibrillar myopathies reveals clues to the mutated gene. *Neuromuscul Disord* 2008;18:656-66. <https://doi.org/10.1016/j.nmd.2008.06.367>
- <sup>97</sup> Lin X, Ruiz J, Bajraktari I, et al. Z-disc-associated, alternatively spliced, PDZ motif-containing protein (ZASP) mutations in the actin-binding domain cause disruption of skeletal muscle actin filaments in myofibrillar myopathy. *J Biol Chem* 2014;289:13615-26. <https://doi.org/10.1074/jbc.M114.550418>
- <sup>98</sup> Martinelli VC, Kyle WB, Kojic S, et al. ZASP interacts with the mechanosensing protein Ankrd2 and p53 in the signalling network of striated muscle. *PLoS One* 2014;9:e92259. <https://doi.org/10.1371/journal.pone.0092259>
- <sup>99</sup> Vatta M, Mohapatra B, Jimenez S, et al. Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction. *J Am Coll Cardiol* 2003;42:2014-27. <https://doi.org/10.1016/j.jacc.2003.10.021>
- <sup>100</sup> Xing Y, Ichida F, Matsuoka T, et al. Genetic analysis in patients with left ventricular noncompaction and evidence for genetic heterogeneity. *Mol Genet Metab* 2006;88:71-7. <https://doi.org/10.1016/j.ymgme.2005.11.009>
- <sup>101</sup> Milhorat AT, Wolff HG. Studies in diseases of muscle: XIII. Progressive muscular dystrophy of atrophic distal type; report on a family; report of autopsy. *Arch Neurol Psychiatry* 1943;49:655-64. <https://doi.org/10.1001/archneurpsyc.1943.02290170025002>
- <sup>102</sup> Van Spaendonck-Zwarts KY, Van Hessem L, Jongbloed JDH, et al. Desmin-related myopathy. *Clin Genet* 2011;80:354-66. <https://doi.org/10.1111/j.1399-0004.2010.01512.x>
- <sup>103</sup> Goldfarb LG, Park KY, Cervenákova L, et al. Missense mutations in desmin associated with familial cardiac and skeletal myopathy. *Nature Genet* 1998;19:402-3. <https://doi.org/10.1038/1300>
- <sup>104</sup> Kouloumenta A, Mavroidis M, Capetanaki Y. Proper perinuclear localization of the TRIM-like protein myospryn requires its binding partner desmin. *J Biol Chem* 2007;282:35211-21. <https://doi.org/10.1074/jbc.M704733200>
- <sup>105</sup> Kedia N, Arhzaouy K, Pittman SK, et al. Desmin forms toxic, seeding-competent amyloid aggregates that persist in muscle fibers. *PNAS* 2019;116:16835-40. <https://doi.org/10.1073/pnas.1908263116>
- <sup>106</sup> Palmio J, Penttilä S, Huovinen S, Haapasalo H, Udd B. An unusual phenotype of late-onset desminopathy. *Neuromuscul Disord* 2013;23:922-3. <https://doi.org/10.1016/j.nmd.2013.06.374>
- <sup>107</sup> Riley LG, Waddell LB, Ghaoui R, et al. Recessive DES cardio/myopathy without myofibrillar aggregates: intronic splice variant silences one allele leaving only missense L190P-desmin. *Eur J Hum Genet* 2019;27:1267-73. <https://doi.org/10.1038/s41431-019-0393-6>
- <sup>108</sup> Goldfarb LG, Dalakas MC. Tragedy in a heartbeat: malfunctioning desmin causes skeletal and cardiac muscle disease. *J Clin Investig* 2009;119:1806-13. <https://doi.org/10.1172/JCI38027>
- <sup>109</sup> Goldfarb LG, Olivé M, Vicart P, et al. Intermediate filament diseases: desminopathy. *Adv Exp Med Biol* 2008;642:131-64. [https://doi.org/10.1007/978-0-387-84847-1\\_11](https://doi.org/10.1007/978-0-387-84847-1_11)
- <sup>110</sup> Walter M, Reichlich P, Hübner A. Identification of a desmin gene mutation in scapuloperoneal syndrome type Kaeser. *Neuromuscul Disord* 2006;16:708-9.
- <sup>111</sup> Li D, Tapscoft T, Gonzalez O, et al. Desmin mutation responsible for idiopathic dilated cardiomyopathy. *Circulation* 1999;100:461-4. <https://doi.org/10.1161/01.cir.100.5.461>
- <sup>112</sup> Taylor MR, Slavov D, Ku L, et al. Prevalence of desmin mutations in dilated cardiomyopathy. *Circulation* 2007;115:1244-51. <https://doi.org/10.1161/circulationaha.106.646778>
- <sup>113</sup> Vicart P, Caron A, Guicheney P, et al. A missense mutation in the  $\alpha$ B-crystallin chaperone gene causes a desmin-related myopathy. *Nature Genet* 1998;20:92-5. <https://doi.org/10.1038/1765>
- <sup>114</sup> Selcen D, Engel AG. Myofibrillar myopathy caused by novel dominant negative alpha B-crystallin mutations. *Ann Neurol* 2003;54:804-10. <https://doi.org/10.1002/ana.10767>
- <sup>115</sup> Reilich P, Schoser B, Schramm N, et al. The p.G154S mutation of the alpha-B crystallin gene (CRYAB) causes late-onset distal myopathy. *Neuromuscul Disord* 2010;20(4):255-9. <https://doi.org/10.1016/j.nmd.2010.01.012>
- <sup>116</sup> Sacconi S, Feasson L, Antoine JC, et al. A novel CRYAB mutation resulting in multisystemic disease. *Neuromuscul Disord* 2012;22:66-72. <https://doi.org/10.1016/j.nmd.2011.07.004>
- <sup>117</sup> Bortolani S, Fattori F, Monforte M, et al. Peculiar muscle imaging findings in a patient with alphaB-crystallinopathy and axial myopathy. *J Neurol Sci* 2020;416:116999. <https://doi.org/10.1016/j.jns.2020.116999>
- <sup>118</sup> Carvalho AAS, Lacene E, Brochier G, et al. Genetic mutations and demographic, clinical, and morphological aspects of myofibrillar myopathy in a French cohort. *Genet Test Mol Biomarkers* 2018;22:374-83. <https://doi.org/10.1089/gtmb.2018.0004>

- <sup>119</sup> Sarparanta J, Jonson PH, Kawan S, et al. Neuromuscular diseases due to chaperone mutations: a review and some new results. *Int J Mol Sc* 2020;21. <https://doi.org/10.3390/ijms21041409>
- <sup>120</sup> D'Agostino M, Scerra G, Cannata Serio M, et al. Unconventional secretion of alpha-crystallin B requires the autophagic pathway and is controlled by phosphorylation of its serine 59 residue. *Sci Rep* 2019;9:16892. <https://doi.org/10.1038/s41598-019-53226-x>
- <sup>121</sup> Ciano M, Allocca S, Ciardulli MC, et al. Differential phosphorylation-based regulation of alphaB-crystallin chaperone activity for multipass transmembrane proteins. *Biochem Biophys Res Commun* 2016;479:325-30. <https://doi.org/10.1016/j.bbrc.2016.09.071>
- <sup>122</sup> D'Agostino M, Lemma V, Chesi G, et al. The cytosolic chaperone alpha-crystallin B rescues folding and compartmentalization of misfolded multspan transmembrane proteins. *J Cell Sci* 2013;126(Pt 18):4160-72. <https://doi.org/10.1242/jcs.125443>
- <sup>123</sup> Del Bigio MR, Chudley AE, Sarnat HB, et al. Infantile muscular dystrophy in Canadian aboriginals is an alphaB-crystallinopathy. *Ann Neurol* 2011;69:866-71. <https://doi.org/10.1002/ana.22331>
- <sup>124</sup> Inagaki N, Hayashi T, Arimura T, et al. Alpha B-crystallin mutation in dilated cardiomyopathy. *Biochem Biophys Res Commun* 2006;342:379-86. <https://doi.org/10.1016/j.bbrc.2006.01.154>
- <sup>125</sup> Berry V, Francis P, Reddy MA, et al. Alpha-B crystallin gene (CRYAB) mutation causes dominant congenital posterior polar cataract in humans. *Am J Hum Genet* 2001;69:1141-5. <https://doi.org/10.1086/324158>
- <sup>126</sup> Ma K, Luo D, Tian T, et al. A novel homozygous initiation codon variant associated with infantile alpha-Bcrystallinopathy in a Chinese family. *Mol Genet Genomic Med* 2019;7:e825. <https://doi.org/10.1002/mgg3.825>
- <sup>127</sup> Marcos AT, Amoros D, Munoz-Cabello B, et al. A novel dominant mutation in CRYAB gene leading to a severe phenotype with childhood onset. *Mol Genet Genomic Med* 2020;8:e1290. <https://doi.org/10.1002/mgg3.1290>
- <sup>128</sup> Miyoshi K, Tada Y, Iwasa M. Autosomal recessive distal myopathy observed characteristically in Japan. *Jpn J Hum Genet* 1975;20:62-63.
- <sup>129</sup> Bansal D, Campbell KP. Dysferlin and the plasma membrane repair in muscular dystrophy. *Trends in Cell Biology* 2004;14:206-13. <https://doi.org/10.1016/j.tcb.2004.03.001>
- <sup>130</sup> Glover L, Brown RH, Jr. Dysferlin in membrane trafficking and patch repair. *Traffic* 2007;8:785-94. <https://doi.org/10.1111/j.1600-0854.2007.00573.x>
- <sup>131</sup> Klinge L, Harris J, Sewry C, et al. Dysferlin associates with the developing T-tubule system in rodent and human skeletal muscle. *Muscle Nerve* 2010;41:166-73. <https://doi.org/10.1002/mus.21166>
- <sup>132</sup> Cacciottolo M, Numitone G, Aurino S, et al. Muscular dystrophy with marked dysferlin deficiency is consistently caused by primary dysferlin gene mutations. *Eur J Hum Genet* 2011;19:974-80. <https://doi.org/10.1038/ejhg.2011.70>
- <sup>133</sup> Cox D, Henderson M, Straub V, et al. A simple and rapid immunoassay predicts dysferlinopathies in peripheral blood film. *Neuromuscul Disord* 2019;29:874-80. <https://doi.org/10.1016/j.nmd.2019.09.008>
- <sup>134</sup> Magri F, Nigro V, Angelini C, et al. The Italian limb girdle muscular dystrophy registry: Relative frequency, clinical features, and differential diagnosis. *Muscle Nerve* 2017;55:55-68. <https://doi.org/10.1002/mus.25192>
- <sup>135</sup> Wang L, Zhang VW, Li S, et al. The clinical spectrum and genetic variability of limb-girdle muscular dystrophy in a cohort of Chinese patients. *Orphanet J Rare Dis* 2018;13:133. <https://doi.org/10.1186/s13023-018-0859-6>
- <sup>136</sup> Izumi R, Takahashi T, Suzuki N, et al. The genetic profile of dysferlinopathy in a cohort of 209 cases: genotype-phenotype relationship and a hotspot on the inner DysF domain. *Hum Mutat* 2020;41:1540-54. <https://doi.org/10.1002/humu.24036>
- <sup>137</sup> Fatehi F, Nafissi S, Urtizberea JA, et al. Dysferlinopathy in Iran: clinical and genetic report. *J Neurol Sci* 2015;359:256-9. <https://doi.org/10.1016/j.jns.2015.11.009>
- <sup>138</sup> Bushby KM. The limb-girdle muscular dystrophies-multiple genes, multiple mechanisms. *Hum Mol Genet* 1999;8:1875-82. <https://doi.org/10.1093/hmg/8.10.1875>
- <sup>139</sup> Nigro V, Savarese M. Genetic basis of limb-girdle muscular dystrophies: the 2014 update. *Acta Myol* 2014;33:1-12. PMID 24843229.
- <sup>140</sup> Klinge L, Dean AF, Kress W, et al. Late onset in dysferlinopathy widens the clinical spectrum. *Neuromuscul Disord* 2008;18:288-90. <https://doi.org/10.1016/j.nmd.2008.01.004>
- <sup>141</sup> Evila A, Palmio J, Vihola A, et al. Targeted next-generation sequencing reveals novel TTN mutations causing recessive distal titinopathy. *Mol Neurobiol* 2017;54:7212-23. <https://doi.org/10.1007/s12035-016-0242-3>
- <sup>142</sup> Evila A, Vihola A, Sarparanta J, et al. Atypical phenotypes in titinopathies explained by second titin mutations. *Ann Neurol* 2014;75:230-40. <https://doi.org/10.1002/ana.24102>
- <sup>143</sup> Hackman P, Marchand S, Sarparanta J, et al. Truncating mutations in C-terminal titin may cause more severe tibial muscular dystrophy (TMD). *Neuromuscul Disord* 2008;18:922-8. <https://doi.org/10.1016/j.nmd.2008.07.010>
- <sup>144</sup> Savarese M, Maggi L, Vihola A, et al. Interpreting genetic variants in titin in patients with muscle disorders. *JAMA Neurol* 2018;75:557-65. <https://doi.org/10.1001/jamaneurol.2017.4899>
- <sup>145</sup> Penisson-Besnier I, Hackman P, Suominen T, et al. Myopathies caused by homozygous titin mutations: limb-girdle muscular dystrophy 2J and variations of phenotype. *J Neurol Neurosurg Psychiatry* 2010;81:1200-2. <https://doi.org/10.1136/jnnp.2009.178434>
- <sup>146</sup> Savarese M, Johari M, Johnson K, et al. Improved criteria for the classification of titin variants in inherited skeletal myopathies. *J Neuromuscul Dis* 2020;7:153-66. <https://doi.org/10.3233/JND-190423>
- <sup>147</sup> Savarese M, Valipakka S, Johari M, et al. Is gene-size an issue for

- the diagnosis of skeletal muscle disorders? *J Neuromuscul Dis* 2020;7:203-16. <https://doi.org/10.3233/JND-190459>
- <sup>148</sup> Välipakka S, Savarese M, Johari M, et al. Copy number variation analysis increases the diagnostic yield in muscle diseases. *Neurol Genet* 2017;3. <https://doi.org/10.1212/nxg.0000000000000204>
- <sup>149</sup> Sagath L, Lehtokari VL, Valipakka S, et al. An extended targeted copy number variation detection array including 187 genes for the diagnostics of neuromuscular disorders. *J Neuromuscul Dis* 2018;5:307-14. <https://doi.org/10.3233/JND-170298>
- <sup>150</sup> Valipakka S, Savarese M, Sagath L, et al. Improving copy number variant detection from sequencing data with a combination of programs and a predictive model. *J Mol Diagn* 2020;22:40-9. <https://doi.org/10.1016/j.jmol.2019.08.009>
- <sup>151</sup> Bryen SJ, Ewans LJ, Pinner J, et al. Recurrent TTN metatranscript-only c.39974-11T>G splice variant associated with autosomal recessive arthrogryposis multiplex congenita and myopathy. *Hum Mutat* 2020;41:403-11. <https://doi.org/10.1002/humu.23938>
- <sup>152</sup> Savarese M, Qureshi T, Torella A, et al. Identification and characterization of splicing defects by single-molecule real-time sequencing technology (PacBio). *J Neuromuscul Dis* 2020;7:477-81. <https://doi.org/10.3233/JND-200523>
- <sup>153</sup> Nonaka I, Sunohara N, Ishiura S, et al. Familial distal myopathy with rimmed vacuole and lamellar (myeloid) body formation. *J Neurol Sci* 1981;51:141-5. [https://doi.org/10.1016/0022-510X\(81\)90067-8](https://doi.org/10.1016/0022-510X(81)90067-8)
- <sup>154</sup> Argov Z, Yarom R. "Rimmed vacuole myopathy" sparing the quadriceps. A unique disorder in iranian jews. *J Neurol Sci* 1984;64:33-43. [https://doi.org/10.1016/0022-510X\(84\)90053-4](https://doi.org/10.1016/0022-510X(84)90053-4)
- <sup>155</sup> Eisenberg I, Avidan N, Potikha T, et al. The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. *Nat Genet* 2001;29:83-7. <https://doi.org/10.1038/ng718>
- <sup>156</sup> Keppler OT, Hinderlich S, Langner J, et al. UDP-GlcNAc 2-epimerase: a regulator of cell surface sialylation. *Science* 1999;284:1372-6. <https://doi.org/10.1126/science.284.5418.1372>
- <sup>157</sup> Sela I, Goss V, Becker-Cohen M, et al. The glycomic sialylation profile of GNE Myopathy muscle cells does not point to consistent hyposialylation of individual glycoconjugates. *Neuromuscul Disord* 2020;30:621-30. <https://doi.org/10.1016/j.nmd.2020.05.008>
- <sup>158</sup> Chen Y, Xi J, Zhu W, et al. GNE myopathy in Chinese population: hotspot and novel mutations. *J Hum Genet* 2019;64:11-6. <https://doi.org/10.1038/s10038-018-0525-9>
- <sup>159</sup> Bhattacharya S, Khadilkar SV, Nalini A, et al. Mutation Spectrum of GNE Myopathy in the Indian Sub-Continent. *J Neuromuscul Dis* 2018;5:85-92. <https://doi.org/10.3233/JND-170270>
- <sup>160</sup> Papadimas GK, Evila A, Papadopoulos C, et al. GNE-myopathy in a Greek Romani family with unusual calf phenotype and protein aggregation pathology. *J Neuromuscul Dis* 2016;3:283-8. <https://doi.org/10.3233/JND-160154>
- <sup>161</sup> Alrohaif H, Pogoryelova O, Al-Ajmi A, et al. GNE myopathy in the bedouin population of Kuwait: genetics, prevalence, and clinical description. *Muscle Nerve* 2018;58:700-7. <https://doi.org/10.1002/mus.26337>
- <sup>162</sup> Khadilkar SV, Nallamilli BRR, Bhutada A, et al. A report on GNE myopathy: individuals of Rajasthan ancestry share the Roma gene. *J Neurol Sci* 2017;375:239-40. <https://doi.org/10.1016/j.jns.2017.02.005>
- <sup>163</sup> Pogoryelova O, Urtizberea JA, Argov Z, et al. 237th ENMC International Workshop: GNE myopathy – current and future research Hoofddorp, The Netherlands, 14-16 September 2018. *Neuromuscul Disord* 2019;29:401-10. <https://doi.org/10.1016/j.nmd.2019.02.010>
- <sup>164</sup> Chakravorty S, Berger K, Arafat D, et al. Clinical utility of RNA sequencing to resolve unusual GNE myopathy with a novel promoter deletion. *Muscle Nerve* 2019;60:98-103. <https://doi.org/10.1002/mus.26486>
- <sup>165</sup> Garland J, Stephen J, Class B, et al. Identification of an Alu element-mediated deletion in the promoter region of GNE in siblings with GNE myopathy. *Mol Genet Genomic Med* 2017;5:410-7. <https://doi.org/10.1002/mgg3.300>
- <sup>166</sup> Miao J, Wei XJ, Wang X, et al. A case report: identification of a novel exon 1 deletion mutation in the GNE gene in a Chinese patient with GNE myopathy. *Medicine (Baltimore)* 2020;99:e22663. <https://doi.org/10.1097/MD.00000000000022663>
- <sup>167</sup> Zhu W, Eto M, Mitsuhashi S, et al. GNE myopathy caused by a synonymous mutation leading to aberrant mRNA splicing. *Neuromuscul Disord* 2018;28:154-7. <https://doi.org/10.1016/j.nmd.2017.11.003>
- <sup>168</sup> Pogoryelova O, Cammish P, Mansbach H, et al. Phenotypic stratification and genotype-phenotype correlation in a heterogeneous, international cohort of GNE myopathy patients: first report from the GNE myopathy Disease Monitoring Program, registry portion. *Neuromuscul Disord* 2018;28:158-68. <https://doi.org/10.1016/j.nmd.2017.11.001>
- <sup>169</sup> Pogoryelova O, Wilson IJ, Mansbach H, et al. GNE genotype explains 20% of phenotypic variability in GNE myopathy. *Neurol Genet* 2019;5:e308. <https://doi.org/10.1212/NXG.0000000000000308>
- <sup>170</sup> Soule T, Phan C, White C, et al. GNE myopathy with novel mutations and pronounced paraspinal muscle atrophy. *Front Neurol* 2018;9:942. <https://doi.org/10.3389/fneur.2018.00942>
- <sup>171</sup> Seppala R, Lehto VP, Gahl WA. Mutations in the human UDP-N-acetylglucosamine 2-epimerase gene define the disease sialuria and the allosteric site of the enzyme. *Am J Hum Genet* 1999;64:1563-9. <https://doi.org/10.1086/302411>
- <sup>172</sup> Williams DR, Reardon K, Roberts L, et al. A new dominant distal myopathy affecting posterior leg and anterior upper limb muscles. *Neurology* 2005;64:1245-54. <https://doi.org/10.1212/01.WNL.0000156524.95261.B9>
- <sup>173</sup> Duff RM, Tay V, Hackman P, et al. Mutations in the N-terminal actin-binding domain of filamin C cause a distal myopathy. *Am J Hum Genet* 2011;88:729-40. <https://doi.org/10.1016/j.ajhg.2011.04.021>

- 174 Mao Z, Nakamura F. Structure and function of filamin C in the muscle Z-disc. *Int J Mol Sc* 2020;21. <https://doi.org/10.3390/ijms21082696>
- 175 Gonzalez-Morales N, Holenka TK, Schock F. Filamin actin-binding and titin-binding fulfill distinct functions in Z-disc cohesion. *PLoS Genet* 2017;13:e1006880. <https://doi.org/10.1371/journal.pgen.1006880>
- 176 Reinstein E, Gutierrez-Fernandez A, Tzur S, et al. Congenital dilated cardiomyopathy caused by biallelic mutations in Filamin C. *Eur J Hum Genet* 2016;24:1792-6. <https://doi.org/10.1038/ejhg.2016.110>
- 177 Tasca G, Odgerel Z, Monforte M, et al. Novel FLNC mutation in a patient with myofibrillar myopathy in combination with late-onset cerebellar ataxia. *Muscle Nerve* 2012;46:275-82. <https://doi.org/10.1002/mus.23349>
- 178 Vorgerd M, Van Der Ven PFM, Bruchertseifer V, et al. A mutation in the dimerization domain of filamin c causes a novel type of autosomal dominant myofibrillar myopathy. *Am J Hum Gen* 2005;77:297-304. <https://doi.org/10.1086/431959>
- 179 van den Bogaart FJ, Claeys KG, Kley RA, et al. Widening the spectrum of filamin-C myopathy: predominantly proximal myopathy due to the p.A193T mutation in the actin-binding domain of FLNC. *Neuromuscul Disord* 2017;27:73-7. <https://doi.org/10.1016/j.nmd.2016.09.017>
- 180 Verdonschot JAJ, Vanhoutte EK, Claes GRF, et al. A mutation update for the FLNC gene in myopathies and cardiomyopathies. *Hum Mutat* 2020;41:1091-111. <https://doi.org/10.1002/humu.24004>
- 181 Rossi D, Palmio J, Evila A, et al. A novel FLNC frameshift and an OBSCN variant in a family with distal muscular dystrophy. *PLoS One* 2017;12:e0186642. <https://doi.org/10.1371/journal.pone.0186642>
- 182 Gemelli C, Prada V, Fiorillo C, et al. A novel mutation in the N-terminal acting-binding domain of filamin C protein causing a distal myofibrillar myopathy. *J Neurol Sci* 2019;398:75-8. <https://doi.org/10.1016/j.jns.2019.01.019>
- 183 Evangelista T, Lornage X, Carlier PG, et al. A heterozygous mutation in the filamin C gene causes an unusual nemaline myopathy with ring fibers. *J Neuropathol Exp Neurol* 2020;79:908-14. <https://doi.org/10.1093/jnen/nlaa052>
- 184 Servidei S, Capon F, Spinazzola A, et al. A distinctive autosomal dominant vacuolar neuromyopathy linked to 19p13. *Neurology* 1999;53:830-7. <https://doi.org/10.1212/wnl.53.4.830>
- 185 Ruggieri A, Brancati F, Zanotti S, et al. Complete loss of the DNAJB6 G/F domain and novel missense mutations cause distal-onset DNAJB6 myopathy. *Acta Neuropathol Commun* 2015;3:44. <https://doi.org/10.1186/s40478-015-0224-0>
- 186 Hageman J, Rujano MA, van Waarde MA, et al. A DNAJB chaperone subfamily with HDAC-dependent activities suppresses toxic protein aggregation. *Mol Cell* 2010;37:355-69. <https://doi.org/10.1016/j.molcel.2010.01.001>
- 187 Harms MB, Sommerville RB, Allred P, et al. Exome sequencing reveals DNAJB6 mutations in dominantly-inherited myopathy. *Ann Neurol* 2012;71:407-16. <https://doi.org/10.1002/ana.22683>
- 188 Sarparanta J, Jonson PH, Golzio C, et al. Mutations affecting the cytoplasmic functions of the co-chaperone DNAJB6 cause limb-girdle muscular dystrophy. *Nat Genet* 2012;44:450-5. <https://doi.org/10.1038/ng.1103>
- 189 Palmio J, Jonson PH, Evila A, et al. Novel mutations in DNAJB6 gene cause a very severe early-onset limb-girdle muscular dystrophy 1D disease. *Neuromuscul Disor* 2015;25:835-42. <https://doi.org/10.1016/j.nmd.2015.07.014>
- 190 Bohlega SA, Alfawaz S, Abou-Al-Shaar H, et al. LGMD1D myopathy with cytoplasmic and nuclear inclusions in a Saudi family due to DNAJB6 mutation. *Acta Myol* 2018;37:221-6. PMID 30838352.
- 191 Zima J, Eaton A, Pal E, et al. Intrafamilial variability of limb-girdle muscular dystrophy, LGMD1D type. *Eur J Med Genet* 2020;63:103655. <https://doi.org/10.1016/j.ejmg.2019.04.012>
- 192 Jonson PH, Palmio J, Johari M, et al. Novel mutations in DNAJB6 cause LGMD1D and distal myopathy in French families. *Eur J Neurol* 2018;25:790-4. <https://doi.org/10.1111/ene.13598>
- 193 Sandell S, Huovinen S, Palmio J, et al. Diagnostically important muscle pathology in DNAJB6 mutated LGMD1D. *Acta Neuropathol Commun* 2016;4:9. <https://doi.org/10.1186/s40478-016-0276-9>
- 194 Palmio J, Jonson PH, Inoue M, et al. Mutations in the J domain of DNAJB6 cause dominant distal myopathy. *Neuromuscul Disord* 2020;30:38-46. <https://doi.org/10.1016/j.nmd.2019.11.005>
- 195 Ghaoui R, Palmio J, Brewer J, et al. Mutations in HSPB8 causing a new phenotype of distal myopathy and motor neuropathy. *Neurology* 2016;86:391-8. <https://doi.org/10.1212/WNL.0000000000002324>
- 196 Carra S, Seguin SJ, Lambert H, et al. HspB8 chaperone activity toward poly(Q)-containing proteins depends on its association with Bag3, a stimulator of macroautophagy. *J Biol Chem* 2008;283:1437-44. <https://doi.org/10.1074/jbc.M706304200>
- 197 Nakhro K, Park JM, Kim YJ, et al. A novel Lys141Thr mutation in small heat shock protein 22 (HSPB8) gene in Charcot-Marie-Tooth disease type 2L. *Neuromuscul Disord* 2013;23:656-63. <https://doi.org/10.1016/j.nmd.2013.05.009>
- 198 Rusmini P, Cristofani R, Galbiati M, et al. The Role of the Heat Shock Protein B8 (HSPB8) in Motoneuron Diseases *Front Mol Neurosci* 2017;10:176. <https://doi.org/10.3389/fnmol.2017.00176>
- 199 Echaniz-Laguna A, Geuens T, Petiot P, et al. Axonal neuropathies due to mutations in small heat shock proteins: clinical, genetic, and functional insights into novel mutations. *Hum Mutat* 2017;38:556-68. <https://doi.org/10.1002/humu.23189>
- 200 Irobi J, Van Impe K, Seeman P, et al. Hot-spot residue in small heat-shock protein 22 causes distal motor neuropathy. *Nat Genet* 2004;36:597-601. <https://doi.org/10.1038/ng1328>
- 201 Tang BS, Zhao GH, Luo W, et al. Small heat-shock protein 22 mutated in autosomal dominant Charcot-Marie-Tooth disease type 2L.



- Hum Genet 2005;116:222-4. <https://doi.org/10.1007/s00439-004-1218-3>
- <sup>202</sup> Al-Tahan S, Weiss L, Yu H, et al. New family with HSPB8-associated autosomal dominant rimmed vacuolar myopathy. *Neurol Genet* 2019;5:e349. <https://doi.org/10.1212/NXG.0000000000000349>
- <sup>203</sup> Echaniz-Laguna A, Lornage X, Lannes B, et al. HSPB8 haploinsufficiency causes dominant adult-onset axial and distal myopathy. *Acta Neuropathol* 2017;134:163-5. <https://doi.org/10.1007/s00401-017-1724-8>
- <sup>204</sup> Cortese A, Laura M, Casali C, et al. Altered TDP-43-dependent splicing in HSPB8-related distal hereditary motor neuropathy and myofibrillar myopathy. *Eur J Neurol* 2018;25:154-63. <https://doi.org/10.1111/ene.13478>
- <sup>205</sup> Nicolau S, Liewluck T, Elliott JL, et al. A novel heterozygous mutation in the C-terminal region of HSPB8 leads to limb-girdle rimmed vacuolar myopathy. *Neuromuscul Disord* 2020;30:236-40. <https://doi.org/10.1016/j.nmd.2020.02.005>
- <sup>206</sup> Bolduc V, Marlow G, Boycott KM, et al. Recessive mutations in the putative calcium-activated chloride channel Anoctamin 5 cause proximal LGMD2L and distal MMD3 muscular dystrophies. *Am J Hum Genet* 2010;86:213-21. <https://doi.org/10.1016/j.ajhg.2009.12.013>
- <sup>207</sup> Penttila S, Palmio J, Suominen T, et al. Eight new mutations and the expanding phenotype variability in muscular dystrophy caused by ANO5. *Neurology* 2012;78:897-903. <https://doi.org/10.1212/WNL.0b013e31824c4682>
- <sup>208</sup> Sarkozy A, Deschauer M, Carlier RY, et al. Muscle MRI findings in limb girdle muscular dystrophy type 2L. *Neuromuscul Disord* 2012;22(Suppl 2):S122-9. <https://doi.org/10.1016/j.nmd.2012.05.012>
- <sup>209</sup> Whitlock JM, Yu K, Cui YY, et al. Anoctamin 5/TMEM16E facilitates muscle precursor cell fusion. *J Gen Physiol* 2018;150:1498-509. <https://doi.org/10.1085/jgp.201812097>
- <sup>210</sup> Griffin DA, Johnson RW, Whitlock JM, et al. Defective membrane fusion and repair in Anoctamin5-deficient muscular dystrophy. *Hum Mol Genet* 2016;25:1900-11. <https://doi.org/10.1093/hmg/ddw063>
- <sup>211</sup> Topf A, Johnson K, Bates A, et al. Sequential targeted exome sequencing of 1001 patients affected by unexplained limb-girdle weakness. *Genet Med* 2020;22:1478-88. <https://doi.org/10.1038/s41436-020-0840-3>
- <sup>212</sup> Savarese M, Di Fruscio G, Tasca G, et al. Next generation sequencing on patients with LGMD and nonspecific myopathies: Findings associated with ANO5 mutations. *Neuromuscul Disord* 2015;25:533-41. <https://doi.org/10.1016/j.nmd.2015.03.011>
- <sup>213</sup> van der Kooi AJ, Ten Dam L, Frankhuizen WS, et al. ANO5 mutations in the Dutch limb girdle muscular dystrophy population. *Neuromuscul Disord* 2013;23:456-60. <https://doi.org/10.1016/j.nmd.2013.03.012>
- <sup>214</sup> Schneider I, Stoltenburg G, Deschauer M, et al. Limb girdle muscular dystrophy type 2L presenting as necrotizing myopathy. *Acta Myol* 2014;33:19-21. PMID 24843231.
- <sup>215</sup> Vihola A, Luque H, Savarese M, et al. Diagnostic anoctamin-5 protein defect in patients with ANO5-mutated muscular dystrophy. *Neuropathol Appl Neurobiol* 2018;44:441-8. <https://doi.org/10.1111/nan.12410>
- <sup>216</sup> Jarmula A, Lusakowska A, Fichna JP, et al. ANO5 mutations in the Polish limb girdle muscular dystrophy patients: effects on the protein structure. *Sci Rep* 2019;9:11533. <https://doi.org/10.1038/s41598-019-47849-3>
- <sup>217</sup> Vazquez J, Lefeuvre C, Escobar RE, et al. Phenotypic spectrum of myopathies with recessive anoctamin-5 mutations. *J Neuromuscul Dis* 2020;7:443-51. <https://doi.org/10.3233/JND-200515>
- <sup>218</sup> Panades-de Oliveira L, Bermejo-Guerrero L, de Fuenmayor-Fernandez de la Hoz CP, et al. Persistent asymptomatic or mild symptomatic hyperCKemia due to mutations in ANO5: the mildest end of the anoctaminopathies spectrum. *J Neurol* 2020;267:2546-55. <https://doi.org/10.1007/s00415-020-09872-7>
- <sup>219</sup> Silva AMS, Coimbra-Neto AR, Souza PVS, et al. Clinical and molecular findings in a cohort of ANO5-related myopathy. *Ann Clin Transl Neurol* 2019;6:1225-38. <https://doi.org/10.1002/acn3.50801>
- <sup>220</sup> Cai S, Gao M, Xi J, et al. Clinical spectrum and gene mutations in a Chinese cohort with anoctaminopathy. *Neuromuscul Disord* 2019;29:628-33. <https://doi.org/10.1016/j.nmd.2019.06.005>
- <sup>221</sup> Papadopoulou C, Laforêt P, Nectoux J, et al. Hyperckemia and myalgia are common presentations of anoctamin-5-related myopathy in French patients. *Muscle Nerve* 2017;56:1096-100. <https://doi.org/10.1002/mus.25608>
- <sup>222</sup> Tsutsumi S, Kamata N, Vokes TJ, et al. The novel gene encoding a putative transmembrane protein is mutated in gnathodiaphyseal dysplasia (GDD). *Am J Hum Genet* 2004;74:1255-61. <https://doi.org/10.1086/421527>
- <sup>223</sup> Jin L, Liu Y, Sun F, et al. Three novel ANO5 missense mutations in Caucasian and Chinese families and sporadic cases with gnathodiaphyseal dysplasia. *Sci Rep* 2017;7:40935. <https://doi.org/10.1038/srep40935>
- <sup>224</sup> Jokela M, Tasca G, Vihola A, et al. An unusual ryanodine receptor 1 (RYR1) phenotype: Mild calf-predominant myopathy. *Neurology* 2019;92:e1600-9. <https://doi.org/10.1212/WNL.0000000000007246>
- <sup>225</sup> Dlamini N, Voermans NC, Lillis S, et al. Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis. *Neuromuscul Disord* 2013;23:540-8. <https://doi.org/10.1016/j.nmd.2013.03.008>
- <sup>226</sup> Jungbluth H, Müller CR, Halliger-Keller B, et al. Autosomal recessive inheritance of RYR1 mutations in a congenital myopathy with cores. *Neurology* 2002;59:284-7. <https://doi.org/10.1212/WNL.59.2.284>
- <sup>227</sup> Mathews KD, Moore SA. Multimincore myopathy, central core disease, malignant hyperthermia susceptibility, and RYR1 muta-

- tions: one disease with many faces? *Arch Neurol* 2004;61:27-9. <https://doi.org/10.1001/archneur.61.1.27>
- 228 Monnier N, Ferreiro A, Marty I, et al. A homozygous splicing mutation causing a depletion of skeletal muscle RYR1 is associated with multi-minicore disease congenital myopathy with ophthalmoplegia. *Hum Mol Genet* 2003;12:1171-8. <https://doi.org/10.1093/hmg/ddg121>
- 229 Matthews E, Neuwirth C, Jaffer F, et al. Atypical periodic paralysis and myalgia: a novel RYR1 phenotype. *Neurology* 2018;90:e412-8. <https://doi.org/10.1212/WNL.0000000000004894>
- 230 Jungbluth H, Zhou H, Sewry CA, et al. Centronuclear myopathy due to a de novo dominant mutation in the skeletal muscle ryanodine receptor (RYR1) gene. *Neuromuscul Disord* 2007;17:338-45. <https://doi.org/10.1016/j.nmd.2007.01.016>
- 231 Jungbluth H, Dowling JJ, Ferreiro A, Muntoni F, Consortium RYRM. 217th ENMC International Workshop: RYR1-related myopathies, Naarden, The Netherlands, 29-31 January 2016. *Neuromuscul Disord* 2016;26:624-33. <https://doi.org/10.1016/j.nmd.2016.06.001>
- 232 Clarke NF, Waddell LB, Cooper ST, et al. Recessive mutations in RYR1 are a common cause of congenital fiber type disproportion. *Hum Mut* 2010;31:e1544-550. <https://doi.org/10.1002/humu.21278>
- 233 Loseth S, Voermans NC, Torbergesen T, et al. A novel late-onset axial myopathy associated with mutations in the skeletal muscle ryanodine receptor (RYR1) gene. *J Neurol* 2013;260:1504-10. <https://doi.org/10.1007/s00415-012-6817-7>
- 234 Dowling JJ, Lillis S, Amburgey K, et al. King-Denborough syndrome with and without mutations in the skeletal muscle ryanodine receptor (RYR1) gene. *Neuromuscul Disord* 2011;21:420-7. <https://doi.org/10.1016/j.nmd.2011.03.006>
- 235 Kossugue PM, Paim JF, Navarro MM, et al. Central core disease due to recessive mutations in RYR1 gene: is it more common than described? *Muscle Nerve* 2007;35:670-4. <https://doi.org/10.1002/mus.20715>
- 236 Laughlin RS, Niu Z, Wieben E, et al. RYR1 causing distal myopathy. *Mol Genet Genomic Med* 2017;5:800-4. <https://doi.org/10.1002/mgg3.338>
- 237 Laing NG, Laing BA, Meredith C, et al. Autosomal dominant distal myopathy: linkage to chromosome 14. *Am J Hum Genet* 1995;56:422-7. PMID 7847377
- 238 Lamont PJ, Udd B, Mastaglia FL, et al. Laing early onset distal myopathy: slow myosin defect with variable abnormalities on muscle biopsy. *J Neurol Neurosurg Psychiatry* 2006;77:208-15. <https://doi.org/10.1136/jnnp.2005.073825>
- 239 Tasca G, Ricci E, Penttila S, et al. New phenotype and pathology features in MYH7-related distal myopathy. *Neuromuscul Disord* 2012;22:640-7. <https://doi.org/10.1016/j.nmd.2012.03.003>
- 240 Quijano-Roy S, Carlier RY, Fischer D. Muscle imaging in congenital myopathies. *Seminars in pediatric neurology*. 2011;18:221-9. <https://doi.org/10.1016/j.spn.2011.10.003>
- 241 Dabaj I, Carlier RY, Gomez-Andres D, et al. Clinical and imaging hallmarks of the MYH7-related myopathy with severe axial involvement. *Muscle Nerve* 2018;58:224-34. <https://doi.org/10.1002/mus.26137>
- 242 Astrea G, Petrucci A, Cassandrini D, et al. Myoimaging in the NGS era: the discovery of a novel mutation in MYH7 in a family with distal myopathy and core-like features – a case report. *BMC Med Genet* 2016;17:25. <https://doi.org/10.1186/s12881-016-0288-0>
- 243 Meredith C, Herrmann R, Parry C, et al. Mutations in the slow skeletal muscle fiber myosin heavy chain gene (MYH7) cause Laing early-onset distal myopathy (MPD1). *Am J Hum Genet* 2004;75:703-8. <https://doi.org/10.1086/424760>
- 244 Fiorillo C, Astrea G, Savarese M, et al. MYH7-related myopathies: clinical, histopathological and imaging findings in a cohort of Italian patients. *Orphanet J Rare Dis* 2016;11:91. <https://doi.org/10.1186/s13023-016-0476-1>
- 245 Carbonell-Corvillo P, Tristan-Clavijo E, Cabrera-Serrano M, et al. A novel MYH7 founder mutation causing Laing distal myopathy in Southern Spain. *Neuromuscul Disord* 2018;28:828-36. <https://doi.org/10.1016/j.nmd.2018.07.006>
- 246 Banfai Z, Hadzsiev K, Pal E, et al. Novel phenotypic variant in the MYH7 spectrum due to a stop-loss mutation in the C-terminal region: a case report. *BMC Med Genet* 2017;18:105. <https://doi.org/10.1186/s12881-017-0463-y>
- 247 Feinstein-Linial M, Buvoli M, Buvoli A, et al. Two novel MYH7 proline substitutions cause Laing Distal Myopathy-like phenotypes with variable expressivity and neck extensor contracture. *BMC Med Genet* 2016;17:57. <https://doi.org/10.1186/s12881-016-0315-1>
- 248 Surikova Y, Filatova A, Polyak M, et al. Common pathogenic mechanism in patients with dropped head syndrome caused by different mutations in the MYH7 gene. *Gene* 2019;697:159-64. <https://doi.org/10.1016/j.gene.2019.02.011>
- 249 Das KJ, Ingles J, Bagnall RD, et al. Determining pathogenicity of genetic variants in hypertrophic cardiomyopathy: importance of periodic reassessment. *Genet Med* 2014;16:286-93. <https://doi.org/10.1038/gim.2013.138>
- 250 Morales A, Kinnamon DD, Jordan E, et al. Variant interpretation for dilated cardiomyopathy: refinement of the American College of Medical Genetics and Genomics/ClinGen Guidelines for the DCM Precision Medicine Study. *Circ Genom Precis Med* 2020;13:e002480. <https://doi.org/10.1161/CIRCGEN.119.002480>
- 251 Mattivi CL, Bos JM, Bagnall RD, et al. Clinical utility of a phenotype-enhanced MYH7-specific variant classification framework in hypertrophic cardiomyopathy genetic testing. *Circ Genom Precis Med* 2020;13:453-9. <https://doi.org/10.1161/CIRCGEN.120.003039>
- 252 Muelas N, Hackman P, Luque H, et al. MYH7 gene tail mutation causing myopathic profiles beyond Laing distal myopathy. *Neurology* 2010;75:732-41. <https://doi.org/10.1212/WNL.0b013e3181ee4d5>

- 253 Negrao L, Machado R, Lourenco M, et al. Laing early-onset distal myopathy with subsarcolemmal hyaline bodies caused by a novel variant in the MYH7 gene. *Acta Myol* 2020;39:24-8. <https://doi.org/10.36185/2532-1900-004>
- 254 Beecroft SJ, van de Loch M, de Winter JM, et al. Recessive MYH7-related myopathy in two families. *Neuromuscul Disord* 2019;29:456-67. <https://doi.org/10.1016/j.nmd.2019.04.002>
- 255 Tajsharghi H, Oldfors A, Macleod DP, et al. Homozygous mutation in MYH7 in myosin storage myopathy and cardiomyopathy. *Neurology* 2007;68:962. <https://doi.org/10.1212/01.wnl.0000257131.13438.2c>
- 256 Yuceyar N, Ayhan O, Karasoy H, et al. Homozygous MYH7 R1820W mutation results in recessive myosin storage myopathy: scapuloperoneal and respiratory weakness with dilated cardiomyopathy. *Neuromuscul Disord* 2015;25:340-4. <https://doi.org/10.1016/j.nmd.2015.01.007>
- 257 Lehtokari VL, Pelin K, Herczegfalvi A, et al. Nemaline myopathy caused by mutations in the nebulin gene may present as a distal myopathy. *Neuromuscul Disord* 2011;21:556-62. <https://doi.org/10.1016/j.nmd.2011.05.012>
- 258 Wallgren-Petersson C, Lehtokari VL, Kalimo H, et al. Distal myopathy caused by homozygous missense mutations in the nebulin gene. *Brain* 2007;130(Pt 6):1465-76. <https://doi.org/10.1093/brain/awm094>
- 259 Romero NB, Lehtokari VL, Quijano-Roy S, et al. Core-rod myopathy caused by mutations in the nebulin gene. *Neurology* 2009;73:1159-61. <https://doi.org/10.1212/WNL.0b013e3181bacf45>
- 260 Kiiski KJ, Lehtokari VL, Vihola AK, et al. Dominantly inherited distal nemaline/cap myopathy caused by a large deletion in the nebulin gene. *Neuromuscul Disord* 2019;29:97-107. <https://doi.org/10.1016/j.nmd.2018.12.007>
- 261 Kontrogianni-Konstantopoulos A, Ackermann MA, Bowman AL, et al. Muscle giants: molecular scaffolds in sarcomerogenesis. *Physiol Rev* 2009;89:1217-67. <https://doi.org/10.1152/physrev.00017.2009>
- 262 Bang ML, Caremani M, Brunello E, et al. Nebulin plays a direct role in promoting strong actin-myosin interactions. *FASEB J* 2009;23:4117-25. <https://doi.org/10.1096/fj.09-137729>
- 263 Wallgren-Petersson C, Pelin K, Nowak KJ, et al. Genotype-phenotype correlations in nemaline myopathy caused by mutations in the genes for nebulin and skeletal muscle  $\alpha$ -actin. *Neuromuscular Disorders*. 2004;14:461-70. <https://doi.org/10.1016/j.nmd.2004.03.006>
- 264 Lehtokari VL, Kiiski K, Sandaradura SA, et al. Mutation update: the spectra of nebulin variants and associated myopathies. *Hum Mut* 2014;35:1418-26. <https://doi.org/10.1002/humu.22693>
- 265 Feingold-Zadok M, Chitayat D, Chong K, et al. Mutations in the NEB gene cause fetal akinesia/arthrogryposis multiplex congenita. *Prenat Diagn* 2017;37:144-50. <https://doi.org/10.1002/pd.4977>
- 266 Abdalla E, Ravenscroft G, Zayed L, et al. Lethal multiple pterygium syndrome: a severe phenotype associated with a novel mutation in the nebulin gene. *Neuromuscul Disord* 2017;27:537-41. <https://doi.org/10.1016/j.nmd.2017.01.013>
- 267 Kiiski K, Lehtokari VL, Loytynoja A, et al. A recurrent copy number variation of the NEB triplicate region: only revealed by the targeted nemaline myopathy CGH array. *Eur J Hum Genet* 2016;24:574-80. <https://doi.org/10.1038/ejhg.2015.166>
- 268 Hamanaka K, Miyatake S, Koshimizu E, et al. RNA sequencing solved the most common but unrecognized NEB pathogenic variant in Japanese nemaline myopathy. *Genet Me* 2019;21:1629-38. <https://doi.org/10.1038/s41436-018-0360-6>
- 269 Park HJ, Hong YB, Choi YC, et al. ADSSL1 mutation relevant to autosomal recessive adolescent onset distal myopathy. *Ann Neurol* 2016;79:231-43. <https://doi.org/10.1002/ana.24550>
- 270 Park HJ, Lee JE, Choi GS, et al. Electron microscopy pathology of ADSSL1 myopathy. *J Clin Neurol* 2017;13:105-6. <https://doi.org/10.3988/jcn.2017.13.1.105>
- 271 Sun H, Li N, Wang X, et al. Molecular cloning and characterization of a novel muscle adenylosuccinate synthetase, AdSSL1, from human bone marrow stromal cells. *Mol Cell Biochem* 2005;269:85-94. <https://doi.org/10.1007/s11010-005-2539-9>
- 272 Lipps G, Krauss G. Adenylosuccinate synthase from *Saccharomyces cerevisiae*: homologous overexpression, purification and characterization of the recombinant protein. *Biochem J* 1999;341(Pt 3):537-43 (<https://www.ncbi.nlm.nih.gov/pubmed/10417315>). Published 1999/07/27).
- 273 Park HJ, Shin HY, Kim S, et al. Distal myopathy with ADSSL1 mutations in Korean patients. *Neuromuscul Disord* 2017;27:465-72. <https://doi.org/10.1016/j.nmd.2017.02.004>
- 274 Mroczek M, Durmus H, Bijarnia-Mahay S, et al. Expanding the disease phenotype of ADSSL1-associated myopathy in non-Korean patients. *Neuromuscul Disord* 2020;30:310-4. <https://doi.org/10.1016/j.nmd.2020.02.006>
- 275 Cirak S, Von Deimling F, Sachdev S, et al. Kelch-like homologue 9 mutation is associated with an early onset autosomal dominant distal myopathy. *Brain* 2010;133:2123-35. <https://doi.org/10.1093/brain/awq108>
- 276 Tateyama M, Aoki M, Nishino I, et al. Mutation in the caveolin-3 gene causes a peculiar form of distal myopathy. *Neurology* 2002;58:323-5. <https://doi.org/10.1212/WNL.58.2.323>
- 277 Chen J, Zeng W, Han C, et al. Mutation in the caveolin-3 gene causes asymmetrical distal myopathy. *Neuropathology* 2016;36:485-9. <https://doi.org/10.1111/neup.12297>
- 278 Gonzalez-Perez P, Gallano P, Gonzalez-Quereda L, et al. Phenotypic variability in a Spanish family with a caveolin-3 mutation. *J Neurol Sci* 2009;276:95-8. <https://doi.org/10.1016/j.jns.2008.09.009>
- 279 Fulizio L, Nascimbeni AC, Fanin M, et al. Molecular and muscle pathology in a series of caveolinopathy patients. *Hum Mutat* 2005;25:82-9. <https://doi.org/10.1002/humu.20119>
- 280 Carbone I, Bruno C, Sotgia F, et al. Mutation in the CAV3 gene causes partial caveolin-3 deficiency and hyperCKemia. *Neurology* 2000;5:1373-6. <https://doi.org/10.1212/wnl.54.6.1373>
- 281 Vorgerd M, Bolz H, Patzold T, et al. Phenotypic variability in

- rippling muscle disease. *Neurology* 1999;52:1453-9. <https://doi.org/10.1212/wnl.52.7.1453>
- <sup>282</sup> Kubisch C, Schoer BG, von Düring M, et al. Homozygous mutations in caveolin-3 cause a severe form of rippling muscle disease. *Ann Neurol* 2003;53:512-20. <https://doi.org/10.1002/ana.10501>
- <sup>283</sup> Ishiguro K, Nakayama T, Yoshioka M, et al. Characteristic findings of skeletal muscle MRI in caveolinopathies. *Neuromuscul Disord* 2018;28:857-62. <https://doi.org/10.1016/j.nmd.2018.07.010>
- <sup>284</sup> Macias A, Gambin T, Szafranski P, et al. CAV3 mutation in a patient with transient hyperCKemia and myalgia. *Neurol Neurochir Pol* 2016;50:468-73. <https://doi.org/10.1016/j.pjnns.2016.06.008>
- <sup>285</sup> Scalco RS, Gardiner AR, Pitceathly RD, et al. CAV3 mutations causing exercise intolerance, myalgia and rhabdomyolysis: expanding the phenotypic spectrum of caveolinopathies. *Neuromuscul Disord* 2016;26:504-10. <https://doi.org/10.1016/j.nmd.2016.05.006>
- <sup>286</sup> Vatta M, Ackerman MJ, Ye B, et al. Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. *Circulation* 2006;114:2104-12. <https://doi.org/10.1161/CIRCULATIONAHA.106.635268>
- <sup>287</sup> Hayashi T, Arimura T, Ueda K, et al. Identification and functional analysis of a caveolin-3 mutation associated with familial hypertrophic cardiomyopathy. *Biochem Biophys Res Commun* 2004;313:178-84. <https://doi.org/10.1016/j.bbrc.2003.11.101>
- <sup>288</sup> Minetti C, Sotgia F, Bruno C, et al. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. *Nat Genet* 1998;18:365-8. <https://doi.org/10.1038/ng0498-365>
- <sup>289</sup> Bitoun M, Maugendre S, Jeannot PY, et al. Mutations in dynamin 2 cause dominant centronuclear myopathy. *Nat Genet* 2005;37:1207-9. <https://doi.org/10.1038/ng1657>
- <sup>290</sup> Bitoun M, Bevilacqua JA, Prudhon B, et al. Dynamin 2 mutations cause sporadic centronuclear myopathy with neonatal onset. *Ann Neurol* 2007;62:666-70. <https://doi.org/10.1002/ana.21235>
- <sup>291</sup> Fischer D, Herasse M, Bitoun M, et al. Characterization of the muscle involvement in dynamin 2-related centronuclear myopathy. *Brain* 2006;129(Pt 6):1463-9. <https://doi.org/10.1093/brain/awl071>
- <sup>292</sup> Bitoun M, Bevilacqua JA, Eymard B, et al. A new centronuclear myopathy phenotype due to a novel dynamin 2 mutation. *Neurology* 2009;72:93-5. <https://doi.org/10.1212/01.wnl.0000338624.25852.12>
- <sup>293</sup> Böhm J, Biancalana V, Dechene ET, et al. Mutation spectrum in the large GTPase dynamin 2, and genotype-phenotype correlation in autosomal dominant centronuclear myopathy. *Hum Mutat* 2012;33:949-59. <https://doi.org/10.1002/humu.22067>
- <sup>294</sup> Chen S, Huang P, Qiu Y, et al. Phenotype variability and histopathological findings in patients with a novel DNM2 mutation. *Neuropathology* 2018;38:34-40. <https://doi.org/10.1111/neup.12432>
- <sup>295</sup> Lin P, Liu X, Zhao D, et al. DNM2 mutations in Chinese Han patients with centronuclear myopathy. *Neurol Sci* 2016;37:995-8. <https://doi.org/10.1007/s10072-016-2513-1>
- <sup>296</sup> Abath Neto O, Martins Cde A, Carvalho M, et al. DNM2 mutations in a cohort of sporadic patients with centronuclear myopathy. *Genet Mol Biol* 2015;38:147-1. <https://doi.org/10.1590/S1415-4757382220140238>
- <sup>297</sup> Casar-Borota O, Jacobsson J, Libelius R, et al. A novel dynamin-2 gene mutation associated with a late-onset centronuclear myopathy with necklace fibres. *Neuromuscul Disord* 2015;25:345-8. <https://doi.org/10.1016/j.nmd.2015.01.001>
- <sup>298</sup> Catteruccia M, Fattori F, Codemo V, et al. Centronuclear myopathy related to dynamin 2 mutations: clinical, morphological, muscle imaging and genetic features of an Italian cohort. *Neuromuscul Disord* 2013;23:229-38. <https://doi.org/10.1016/j.nmd.2012.12.009>
- <sup>299</sup> Mori-Yoshimura M, Okuma A, Oya Y, et al. Clinicopathological features of centronuclear myopathy in Japanese populations harboring mutations in dynamin 2. *Clin Neurol Neurosurg* 2012;114:678-83. <https://doi.org/10.1016/j.clineuro.2011.10.040>
- <sup>300</sup> Hanisch F, Müller T, Dietz A, et al. Phenotype variability and histopathological findings in centronuclear myopathy due to DNM2 mutations. *J Neurol* 2011;258:1085-90. <https://doi.org/10.1007/s00415-010-5889-5>
- <sup>301</sup> Biancalana V, Romero NB, Thuestad IJ, et al. Some DNM2 mutations cause extremely severe congenital myopathy and phenocopy myotubular myopathy. *Acta Neuropathol Commun* 2018;6:93. <https://doi.org/10.1186/s40478-018-0593-2>
- <sup>302</sup> Gallardo E, Claeys KG, Nelis E, et al. Magnetic resonance imaging findings of leg musculature in Charcot-Marie-Tooth disease type 2 due to dynamin 2 mutation. *J Neuro* 2008;255:986-92. <https://doi.org/10.1007/s00415-008-0808-8>
- <sup>303</sup> Ramachandran R, Schmid SL. The dynamin superfamily. *Curr Biol* 2018;28:r411-6. <https://doi.org/10.1016/j.cub.2017.12.013>
- <sup>304</sup> Lee JS, Ismail AM, Lee JY, et al. Impact of dynamin 2 on adenovirus nuclear entry. *Virology* 2019;529:43-56. <https://doi.org/10.1016/j.virol.2019.01.008>
- <sup>305</sup> Zhao M, Maani N, Dowling JJ. Dynamin 2 (DNM2) as cause of, and modifier for, human neuromuscular disease. *Neurotherapeutics* 2018;15:966-75. <https://doi.org/10.1007/s13311-018-00686-0>
- <sup>306</sup> González-Jamett AM, Baez-Matus X, Olivares MJ, et al. Dynamin-2 mutations linked to centronuclear myopathy impair actin-dependent trafficking in muscle cells. *Scientific Reports* 2017;7. <https://doi.org/10.1038/s41598-017-04418-w>
- <sup>307</sup> Durieux AC, Vignaud A, Prudhon B, et al. A centronuclear myopathy-dynamin 2 mutation impairs skeletal muscle structure and function in mice. *Hum Mol Genet* 2010;19:4820-36. <https://doi.org/10.1093/hmg/ddq413>
- <sup>308</sup> Claeys KG, Zuchner S, Kennerson M, et al. Phenotypic spectrum of dynamin 2 mutations in Charcot-Marie-Tooth neuropathy. *Brain* 2009;132(Pt 7):1741-52. <https://doi.org/10.1093/brain/awp115>
- <sup>309</sup> Koutsopoulos OS, Kretz C, Weller CM, et al. Dynamin 2 homozygous mutation in humans with a lethal congenital syndrome. *Eur J Hum Genet* 2013;21:637-42. <https://doi.org/10.1038/ejhg.2012.226>
- <sup>310</sup> Lochmüller H, Badowska DM, Thompson R, et al. RD-Connect, NeurOmics and EUREnOmics: collaborative European initiative



- for rare diseases. *Eur J Hum Genet* 2018;26:778-85. <https://doi.org/10.1038/s41431-018-0115-5>
- <sup>311</sup> Peterlin B, Gualandi F, Maver A, et al. Genetic testing offer for inherited neuromuscular diseases within the EURO-NMD reference network: a European survey study. *PLoS One* 2020;15:e0239329. <https://doi.org/10.1371/journal.pone.0239329>
- <sup>312</sup> Austin CP, Cutillo CM, Lau LPL, et al. Future of Rare Diseases Research 2017-2027: an IRDiRC perspective. *Clin Transl Sci* 2018;11:21-7. <https://doi.org/10.1111/cts.12500>
- <sup>313</sup> Gonorazky HD, Naumenko S, Ramani AK, et al. Expanding the boundaries of RNA sequencing as a diagnostic tool for rare mendelian disease. *Am J Hum Genet* 2019;104:466-83. <https://doi.org/10.1016/j.ajhg.2019.01.012>
- <sup>314</sup> Cummings BB, Marshall JL, Tukiainen T, et al. Improving genetic diagnosis in Mendelian disease with transcriptome sequencing. *Sci Transl Med* 2017;9. <https://doi.org/10.1126/scitranslmed.aal5209>
- <sup>315</sup> Matalonga L, Laurie S, Papakonstantinou A, et al. Improved diagnosis of rare disease patients through systematic detection of runs of homozygosity. *J Mol Diagn* 2020;22:1205-15. <https://doi.org/10.1016/j.jmoldx.2020.06.008>
- <sup>316</sup> Mantere T, Kersten S, Hoischen A. Long-read sequencing emerging in medical genetics. *Front Genet* 2019;10:426. <https://doi.org/10.3389/fgene.2019.00426>
- <sup>317</sup> Thompson R, Spendiff S, Roos A, et al. Advances in the diagnosis of inherited neuromuscular diseases and implications for therapy development. *Lancet Neurol* 2020;19:522-32. [https://doi.org/10.1016/S1474-4422\(20\)30028-4](https://doi.org/10.1016/S1474-4422(20)30028-4)
- <sup>318</sup> Boycott KM, Hartley T, Biesecker LG, et al. A diagnosis for all rare genetic diseases: the horizon and the next frontiers. *Cell* 2019;177:32-7. <https://doi.org/10.1016/j.cell.2019.02.040>